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ABSTRACT

CHARACTERIZATION OF P39, A Borrelia burgdorferi SPECIFIC PROTEIN.

Jill M. Troyer
Old Dominion University
and
Eastern Virginia Medical School
1996
Director: Dr. Robert Ratzlaff

Borrelia burgdorferi, the causative agent o f Lyme disease, expresses a species
specific, 39 kiloDalton protein of unknown function called P39. This protein is highly
immunogenic and the presence of anti-P39 antibodies in patient sera is used as an
indicator of B. burgdorferi infection. P39 is also a candidate for vaccine developement
due to conserved expression o f P39 among B.burgdorferi isolates. Since little is
presently known about this important molecule, the present study was designed to
characterize P39 and was carried out in six separate investigations. First, infectious
and noninfectious isolates o f B.burgdorferi were established in vitro, and the infectivity
o f each was assessed in a murine model. Second, the location of P39 within the
spirochete was determined in infectious and noninfectious isolates by cell fractionation,
and western blot analysis. A correlation was established between P39 localization and
infectivity; infectious and noninfectious isolates localized P39 to both the outer
envelope and inner membrane, but noninfectious isolates had increased levels of P39
in the inner membrane and cytosol as compared to infectious isolates. Third, flow
cytometry was used to determine if P39 expression is uniform throughout a population
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o f spirochetes. Within a cloned population, organisms expressed similar levels o f P39
on the outer surface. In contrast, uncloned populations displayed variable surface P39
expression, and uncloned noninfectious B31, WCH1, and JD1 all expressed lower
levels of P39 as compared to the respective infectious organisms. Fourth, detergent
extraction studies were employed to determine the solubility of the P39 molecule. P39
was shown to be hydrophobic in nature and the solubility o f the molecule was not
altered in infectious or noninfectious isolates nor was it altered in different cell
fractions. Fifth, P39 was immunoprecipitated from infectious and noninfectious
isolates in an attempt to characterize molecules which associate with P39. P39
coprecipitated with four molecules in all isolates, and six additional molecules
common only to noninfectious isolates. Finally, in an attempt to determine if P39
elicits immunopathological responses in an infected host, site directed DNA
mutagenesis was used to inactivate the gene encoding P39. No viable P39 deletion
mutants were obtained, thereby precluding any studies regarding immunopathology
caused by P39. The results o f this study demonstrate P39 is a hydrophobic, membrane
associated protein, and is expressed by both infectious and noninfectious isolates.
Furthermore, infectious and noninfectious isolates exhibited differences in P39
localization, and coprecipitation.
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I. INTRODUCTION

A. History of Lyme disease
Lyme disease is a vector-bome illness with symptoms ranging from mild
arthritis to chronic cardiovascular and neurological abnormalities. It was first
described as a clinical entity in 1977 by reason of a geographic clustering o f children in
Lyme, Connecticut thought to have juvenile rheumatoid arthritis (1,2). Due to the
rural location o f Lyme and distinct rashes which were identified as a feature of the
illness it was assumed that the disease was transmitted by an arthropod. It readily
became apparent that Lyme disease was in fact a multisystem disorder that affected the
nervous system and heart as well as the joints and skin. Epidemiological studies o f
patients suggested Lyme disease was caused by an infectious agent transmitted by ticks
and identified the vector as belonging to the genus Ixodes (3). In 1982, almost five
years after the search began, a previously unrecognized spirochete (thereafter titled
Borrelia burgdorferi) was isolated from adult Ixodes scapularis ticks which were
collected from an endemic focus o f Lyme disease (4). Sixty one percent of I.
scapularis collected in this area contained this newly discovered spirochete (4).
Patient sera was demonstrated to contain antibodies recognizing this organism, and in
laboratory studies rabbits developed the characteristic Lyme rash after exposure to this
spirochete via tick bite (4). Subsequently, the spirochete was actually isolated from
several Lyme patients and the spirochetal etiology of Lyme disease was demonstrated
conclusively (5). In recent years, there has been an increasing number o f reported
Lyme disease cases. In 1994 alone there were greater than 13,000 reported cases of
Lyme disease making it the most frequently diagnosed vector-bome disease in the
United States (6), and consequently a disease of increasing importance.
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B. Lyme Disease
1. Introduction
Humans who have been infected with B.burgdorferi may develop the
pathology known as Lyme disease (7, 8, 9,10). This disease is a multisystemic
disorder, most notably affecting the skin, joints, heart, and nervous system. The
clinical course of Lyme disease can be roughly divided into three stages. The first
stage occurs in the first days or months following exposure and is characterized by a
migrating rash (erythema mi grans), fatigue, malaise, and flu-like symptoms. The
second stage, occurring weeks to months after initial exposure, is characterized by
swelling o f joints (infiltration of monocytes into the joint space, synovial
hyperplasia, intra- and peri-articular lesions), migratory musculoskeletal pain, as well
as cardiovascular abnormalities (tachyarithmiaS, myopericarditis, atrioventricular
conduction defect)(l 1), and neurologic complications (meningitis, encephalitis, optic
neuritis, Bell’s palsy) (12,13). The third stage, occurring months to years post
infection, is distinguished by severe arthritis, cartilage destruction, joint erosion, and
chronic neurological disorders including numbness of limbs, facial palsies, heart
palpitations, loss o f vision, and memory impairment (12,13, 14).
Borrelia burgdorferi has been divided into at least six genospecies including
the following: B.burgdorferi sensu stricto, B.afzelii, and B.garinii. All three species
can cause Lyme disease, and whether these species vary significantly in their
physiology and ability to cause pathology is currently under scrutiny. European
patients infected with B.afzelii or B.garinii have a preponderance o f chronic skin
manifestations as compared to U.S. patients infected with B.burgdorferi sensu stricto
(15,16,17). In addition, arthritis is prevalent in B.burgdorferi sensu stricto infection,
and neurological abnormalities are prevalent in both B.burgdorferi sensu stricto and
B.garinii infections (17). These noted differences in pathology may be due to
differences between the species of B.burgdorferi causing the disease. Alternatively the
differences seen may be due to the genetic background and immune response of
patients, or due to discernment of the doctor treating the patient. Further information
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regarding the basic biology of the spirochete as well as the disease process itself must
first be elucidated before such questions concerning strain variations and pathogenicity
can be properly addressed.

2. Diagnosis
The symptoms o f Lyme disease (i.e. myalgia, arthritis, myocarditis, and
neurological abnormalities) mimic many other disorders (1,18,19,20,21). The
progression of disease and the symptoms associated with it vary dramatically between
individuals making a correct diagnosis difficult. Manifestations of Lyme disease often
times are not recognized as being part of a single entity. Indeed, after identification of
B.burgdorferi investigators began to implicate this spirochete as the causative agent of
other previously recognized illnesses such as Bannwarth’s syndrome (a neurological
disorder), and acrodermatitis (a skin disorder). Obviously, the most direct course for
diagnosis would be isolation o f B.burgdorferi from the patient. However, tissue
culturing is expensive and requires considerable time and experience; therefore, for
many laboratories it is impractical (22). In one study, only 6 of 154 tissue samples
from patients have yielded spirochetes (23). Currently, serodiagnosis is the method
used to assess B.burgdorferi infection (22,24,25,26). Indirect immunofluorescence
assay (IFA) or enzyme linked immunosorbent assay (ELISA) are used as a primary
screening method for serum samples. Samples which test positive for Lyme antibodies
can be further characterized by a western blot analysis. The Center for Disease Control
recommends a two test protocol for Lyme diagnosis; an EIA followed by a western
blot for confirmation of positive results. A blot is considered positive if antibodies to
two out of the three following bands are present: 39 kD (P39), 41 kD (flagellin), and
21-24 kD(OspC) (27). These assays have their limitations as well. Since flagellin is
expressed by other organisms, crossreactivity to this antigen is common for patients
with other spirochetal illnesses. OspC migration in polyacrylimide gels is variable, as
well as its expression among B.burgdorferi isolates, making identification difficult. In
addition, during the first few weeks of infection, the humoral immune response to the
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organism may be weak resulting in a false negative in serologic assays. False positives
can also result when patients are afflicted with other spirochetal illnesses. Another
dilemma is a curtailed immune response due to the administration o f antibiotic
treatment early in the infection. All o f these factors combine to make actual diagnosis
of Lyme disease a challenge.

3. Treatment
Treatment o f Lyme disease patients with high doses o f oral antibiotics
(tetracycline, amoxicillin, doxycycline, or in cases with neurological involvement,
ceftriaxone) clears the infection and alleviates most symptoms o f the disease if
administered early in the course of infection (12,14,28,29,30). If treatment is given
later than six months after initial exposure, the symptoms are usually not completely
reversible. Persistent symptoms may be caused by a process which is no longer
antibiotic-sensitive (not due to the spirochete). For example, B. burgdorferi infection
may trigger fibromyalgia, a chronic pain syndrome which is not antibiotic responsive
(31). Since no identifiable toxins are expressed by the spirochete (32) the pathology
observed in affected tissues may result from specific and nonspecific immunological
responses to B.burgdorferi (19,33). Antibodies directed against myelin and myelin
basic protein have been reported in patient sera (34,35). Research into the dynamics of
specific and nonspecific immune responses o f affected individuals should yield clues to
the cause o f pathology.

4. Vaccine development
Due to difficulty in diagnosis and the occasional treatment failures, prevention
of Lyme disease by vaccination has become an important alternative. The most studied
vaccine candidate is a recombinant OspA molecule (rOspA). Active immunisation
with rOspA or passive transfer of rOspA specific antibodies are protective against
B.burgdorferi infection in inbred strains o f mice (36,37,38,39). Immunized mice are
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protected from needle inoculation o f infectious spirochetes (37) as well as natural
infection via infected ticks (40). However, this vaccine affords protection only at the
beginning stages o f tick feeding before the spirochetes ever enter the host (41). The
tick imbibes blood containing rOspA specific antibodies, and the antibodies destroy the
spirochetes while they are still in the tick midgut. Within three to five days of the
feeding, spirochetes can be found in tissues other than the midgut, such as salivary
glands, malphigian tubules, central ganglion, and ovary (42,43,44). Once they are
out of the tick gut they are no longer susceptible to the rOspA antibodies as the
spirochetes decrease surface expression of the OspA molecule (41). In addition, this
protection was only effective against a few isolates o f B.burgdorferi which share
identical OspA sequences (45). This lack o f cross protection occurs when using other
outer surface proteins as immunogens:OspB, OspC, OspD, OspE, and OspF (46,47,
48). Because of this lack o f cross protection afforded by these molecules, research is
currently underway for other vaccine candidates.

C. The Lyme cycle
In nature, the B.burgdorferi population is maintained by cycling between
hematophagous tick vectors (Ixodes spp.) and various vertebrate hosts such as mice and
rats (49). The primary tick vectors Ixodes scapularis (northeastern U.S.), I.ricinus
(Europe), and I. pacificus (western U.S.) all have a four stage life cycle: egg, larva,
nymph, and adult. Ticks feed once during each stage (with the exception of the egg
stage). If a tick does not feed it is not able to molt and continue development into the
next life stage. Ticks feed by using their elongated, serrated chelicerae to cut into the
epidermis of the host, ripping open blood vessels beneath the surface. The host is
ordinarily unaware o f this event as ticks inject various pharmacological agents into the
wound site, via the hypostome, to prevent pain and inflammation from occurring.
These agents include prostaglandins and prostacyclins to prevent platelet aggregation,
blood coagulation, and vasoconstriction; anti-histamines which decrease inflammation;
and other unidentified substances which destroy bradykinin and block pain. Ticks also
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secrete a substance produced in the salivary glands which acts as a cement to secure the
mouthparts o f the tick into the wound site. Over a period of two to five days, ticks
slowly imbibe a blood meal from the wound site. After engorgement, the process of
detachment is initiated by secretion of an uncharacterized substance which dissolves
the cement and allows the tick to exit the wound without damage to the chelicerae.
Ticks may become infected with B.burgdorferi after ingesting a blood meal
from a host carrying the spirochete. In the wild, the infection rate o f ticks in endemic
Lyme areas average 12-25% for nymphs, and 25-50% for adults (50,51). The average
spirochetal burden is 2,000 5.6./tick in endemic areas (52). After feeding, ticks retain
the blood meal in the midgut which acts primarily as a storage organ. Digestion of the
blood occurs intracellularly by pinocytosis of cells lining the gut allowing spirochetes
and other bacteria to remain undisturbed by enzymatic digestion. Spirochetes may
remain in the midgut (42) or migrate out o f the mesothelium and into the surrounding
tissue. The majority o f ticks (>80%) have spirochetes localized primarily in the midgut
until after the next blood meal (4,42,44). For example, a larval tick becomes infected
with its first blood meal and the spirochetes remain in the midgut until feeding
commences in the nymph stage. Notably, 80% of infected, fed ticks contain spirochetes
in the salivary glands (44). This is a significant figure considering ticks may then
infect a host by secreting the spirochetes from the salivary glands directly into the
wound site during attachment to the host (43,44, 53,54). Additionally, some scientists
postulate that ticks may also regurgitate midgut contents, including spirochetes,
directly into the wound during feeding (42). Spirochetes may persist and multiply
throughout the life o f the tick. Therefore, if a tick is infected during the larval stage it
has the potential to transmit B.burgdorferi to its subsequent hosts during both the
nymph and adult stages.
After inoculation into the host via the bite o f an infected tick, the spirochetes
migrate out o f the wound site and invade the surrounding tissue. Spirochetes are
motile in viscous mediums (55), and their dissemination throughout the host is due to a
combination o f passive transport via the circulatory or lymphatic systems, and active
migration through the extracellular milieu. B. burgdorferi are capable of adhering to a
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wide range o f cell types such as human umbilical vein endothelial cells (56), tick cells
(57) and human epithelial cells (58). B. burgdorferi has been shown to adhere with
high specificity (via 19 and 20 kD proteins) to the proteoglycan decorin (decorin is
bound to collagen fibers), but not to collagens type I or II (59). B. burgdorferi has also
been shown to penetrate endothelial cell monolayers (60). One study demonstrated
that within 24 hours organisms were able to penetrate the blood-brain barrier of rats
when injected intravenously (61). However, the spirochetal adhesion molecules and
the cell surface receptors involved in these processes have not been described

D. Animal models for Lyme disease
Several animal models, including rabbit, hamster, rat, and mouse, have been
developed to study experimental and natural infection with B.burgdorferi. After
inoculation with B.burgdorferi, rabbits develop a skin lesion similar to that found in
Lyme patients but do not develop any other specific pathology. Hamster, rats, and
mice, however, have proven valuable for following the dissemination of the spirochete
after infection as well as immune responses, and pathology. These animal models only
partially mimic the human disease. No animal model has yet been described which
duplicates the presentation of the human disease. The murine model is the most
frequently used system due to the knowledge surrounding the murine genetic and
immune systems, and it has the advantage of being a natural reservoir for the spirochete
in nature (36). Upon infection mice develop multisystemic infections and remain
infected for well over a year (9,62). In addition, spirochetes can be transmitted to ticks
feeding on the infected animals.
Xenodiagnosis is the term used for using ticks for detection of spirochetes in an
infected animal. It is commonly used to assess the infectivity o f newly isolated
spirochetes. In general, transmission of spirochetes to feeding ticks is lower in
inoculated mice than in naturally infected mice. Between 42-84% of ticks feeding on
naturally infected hosts become infected, as compared to 6-35% for ticks feeding on
experimentally inoculated hosts 14 to 100 days post inoculation (63,64).
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Tissue culture is another form o f assessing the infectivity of B.burgdorferi.
Spirochetes have been cultured from all o f the following mouse tissuesrbladder, spleen,
kidney, liver, heart, eyes, brain, joint, skin and blood (7,8, 9, 10,36,37,62,65,66,67,
68,69, 70,71, 72). The bladder has been demonstrated as being the most consistent
source for isolation of B. burgdorferi in murine tissue culture (7,24,37,65,66,67,68,
69, 73, 74). Recovery of spirochetes from 94% o f bladders o f infected mice as
compared to 61% from spleen tissue, and even lower percentages for blood and kidney
(67,69.). It is unclear whether this high recovery rate from bladder tissue is due to a
possible spirochetal predilection for this organ, or due to an artifact of tissue culturing
since the spirochetes may be sensitive to components present in the immascerated
tissue o f certain organs. Interestingly, B.burgdorferi gradually lose their infectivity
during prolonged in vitro cultivation (7 ,9 ,2 4 ,6 5 ,6 6 ,6 7 ,6 9 ,7 3 ,7 5 ,7 6 ,7 7 ). This loss
of infectivity is monitored by tissue culture, and xenodiagnosis.
Histopathology of Lyme disease in mice is wide spread; carditis and arthritis
are common, and joints may become inflamed and swollen. Affected joints contain
infiltrating polymorphonuclear leucocytes, immune complexes, and occasionally
spirochetes. Though inflammation in various tissues is common, spirochetes are not
always detected in or around areas of inflammation (78). This fact once again raises
the issue of whether the spirochete or the immune response to the spirochete is
responsible for tissue pathology.
Borrelia burgdorferi may persist in a host for years after the initial infection
(62,68, 71, 79). The mechanism by which B.burgdorferi is capable of surviving the
vigorous B and T cell responses generated in an immunocompetent host is currently
unknown, and is under intensive scrutiny. Animals inoculated with spirochetes
develop an early humoral response (<14 days) to OspA, OspB, P39 and flagellin.
Naturally infected animals, including humans, respond with antibodies against the 20
kD, 22 kD (OspC), 35 kD, P39, and 58 kD proteins o f B.burgdorferi, whereas few
recognize flagellin, OspA, OspB until very late into the infection, and sometimes not at
all (19,70,80,81). The spirochetes are susceptible to phagocytosis and complement
mediated cytolysis (19,33, 82). Additionally, monoclonal antibodies specific for P39,
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OspA, and OspB are bactericidal for B.burgdorferi in vitro even in the absence of
complement (83). There is no evidence to indicate B.burgdorferi can vary surface
antigens to escape immune response (84,85). However, nonspecific interactions
between extracellular B.burgdorferi proteins and IgM antibodies have been reported
(86), raising the possibility that nonspecific immune complexes may contribute to
immune evasion by camouflaging the cell surface o f the spirochete (86). Much
remains to be learned regarding the spirochetes ability to survive an immune response.
Indeed, specific factors required by the spirochete to maintain an infection in a
mammalian host are currently unknown.
E. Biology of B.burgdorferi
The causative agent o f Lyme disease is the gram-negative spirochete, Borrelia
burgdorferi (4). It was described as a new species o f the genus Borrelia on the basis of
DNA-DNA homology and G + C content similarities (87). It was originally believed
only a single species o f Borrelia caused Lyme disease. However, at least six different
genospecies of B.burgdorferi sensu lato have now been recognized which are classified
according to sequence differences in 16s rRNA genes and restriction fragment length
polymorphism. Three o f these are B.burgdorferi sensu stricto (88,89), B.afzelii (90,
91), and B.garinii (89, 92). The DNA homology among the different strains is 76 to
100%. All three groups are found in Europe and Asia, but only B.burgdorferi sensu
stricto has been isolated in the U.S (89). All three can cause Lyme disease but whether
these strains vary significantly in their physiology or ability to cause pathology is
currently under scrutiny.
Borrelia are the longest and thinnest of the spirochetes ranging in size from 0.2
to 0.5 pm wide and 8 to 30 pm long (93). The cell is comprised of five basic structures:
outer membrane, periplasmic space, flagella, inner cell membrane, and cytoplasmic
compartment. The membrane composition of B. burgdorferi differs from that of other
gram negative spirochetes in that it does not contain lipopolysaccharide (LPS) or
phosphatidyethanolamine (94,95). In addition^B.burgdorferi have a substantial
number of lipidated membrane proteins yet few transmembrane proteins in the outer
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envelope (96,97,98). B.burgdorferi expresses over 30 major proteins, but few have
been well characterized. Several techniques have been used to characterize outer
membrane proteins, including surface radioiodination or biotinylation of surface
exposed proteins. From such experiments thirteen proteins have been identified: 22,
24,29, 3 1 ,3 4 ,3 7 ,3 9 ,4 1 ,5 2 ,6 6 ,7 0 ,7 3 , and a 93 kD molecule (99). Unfortunately,
the further identification o f these surface molecules using monoclonals was not
performed. Six lipoproteins (designated outer surface proteins or Osp) o f unknown
function have been identified using monoclonal antibodies: OspA, OspB, OspC, OspD,
OspE, and OspF (46,75,100,101). However, the Osps are not exclusively located in
the outer envelope as their name might suggest, lipidated Osps are also located in the
inner membrane (102). The molecular weight of these molecules has been shown to
vary between different isolates of B.burgdorferi (103,104) making the use of
monoclonal antibodies essential in the identification of these molecules. Expression of
the Osps are affected by changes in temperature (51,105,106). When a tick imbibes a
blood meal the temperature in the gut increases. This increase in temperature results in
a decreased surface expression o f OspA and an increased surface expression of OspC,
OspE, and OspF. This change is expression o f these molecules is not rapid but occurs
over several cycles of cell division (105). Early studies indicated that OspA and OspB
may be important for adherence or invasion o f host cells (107,108), and OspC for
establishment of infection in a host. However, a mutant isolate which does not express
OspA, OspB, OspC or OspD was shown to have decreased adhesion to human
umbilical vein endothelial cells in vitro yet the infectivity of the organism was
unaffected (109). Even though OspC is not critical for infectivity, it is theorized that
OspC may be important in the migration of the spirochete from the midgut to the
salivary gland (105).
Other Borrelia proteins include flagellin (41 kD), P39 (39 kD), two heat shock
protein homologs (60 and 73 kD), a 93 kD and a 13 kD protein. Two proteins which
appear conserved among all strains of B.burgdorferi are P39 and flagellin. P39 is an
immunogenic protein of unknown function, and a member of a small family of proteins
known as Borrelia membrane proteins (bmp). There are four members in this group:
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bmpA(P39), bmpB, bmpC, and bmpD. The function of these molecules is unknown
but they are highly conserved among all three B.burgdorferi genospecies (110). The
four genes are located on the chromosome and are arranged in the following
ordenbmpD, bmpC, P39, bmpB. The bmpD has been shown to be monocistronic
transcript (110). BmpC is also believed to be monocistronic (111), but P39 and bmpB
are believed to constitute a single operon since P39 has a promoter region whereas
bmpB does not (112). All contain basic charged residues followed by a hydrophobic
region in the very N-terminus o f the protein which is a typical signal sequence of
membrane proteins (110,111,112). In addition, they all contain putative signal II
peptidase site (LFIVAC) which suggests that they may also be lipoproteins yet no
evidence of lipid modification has been shown (110,112). P39, in contrast to the Osps,
is not differentially expressed in relation to temperature (105), and no P39-less mutants
have ever been described in the literature.
Flagellin is the core protein unit of the spirochetes flagella. Borrelia have
between 7 and 11 flagella that are sheathed and located between the inner and outer cell
membranes, which is characteristic o f most spirochetes (93). Only a single flagellar
protein constitutes the core structure of the B.burgdorferi flagella, unlike other
organisms which have a complex of several protein subunits constituting the flagellar
filament (113). Each flagellum is anchored to the inner membrane at one end of the
spirochete and runs the length o f the organism (93). In the middle o f the spirochete the
flagella from one end overlaps with flagella from the other end and forms a distinct
bundle (114). The arrangement of the flagella dictates the helical shape of the cell and
allows the spirochete to move in a spiraling motion. It has been shown that the
spirochetes need a viscous medium, similar to the intercellular matrix of skin, in order
to be motile (55). Spirochetes lose their motility in less viscous fluids such as blood,
and appear to simply spin in place instead of progressing in any direction (55).
Growth o f B.burgdorferi in vitro is slow and requires microaerophilic
conditions, temperatures between 30 and 35°C, and a complex liquid medium known
as Barbour-Stoenner-Kelly medium (BSK). The generation time is 12-24 hours (32)
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and Borrelia divide by forming a septum as opposed to division by constriction (93).
As previously mentioned, the organisms gradually lose their infectivity during
prolonged in vitro cultivation (7 ,9 ,2 4 ,6 5 ,6 6 ,6 7 ,7 3 ,7 5 - 77). The loss is irreversible
and occurs as early as the fifth in vitro passage or as late as the 10th passage. The
direct reason for this loss is unclear, but investigators have documented a variety of
changes that occur during culture including loss of DNA plasmids, changes in
morphology, protein expression, and antigenicity (7,65,75-77,111, 115-117). Loss
of extrachromosomal elements and subtle changes in antigenicity do occur in the
zoonotic cycle, but any variation is limited compared with changes seen during in vitro
cultivation (111). Investigators have tried to identify factors responsible for the
infectivity of the organism by comparing whole cell sonicates of infectious and
noninfectious organisms and have documented specific DNA plasmids and proteins
which are no longer present in some noninfectious isolates (65,68,75,76,115-117).
However, the loss o f plasmids or protein expression is not consistent among isolates
which have lost infectivity. This raises the possibility that infectivity is dependent
upon a number of factors; the loss of any one factor results in loss o f infectivity. To
date, no factors critical to the infectivity of the organism have been identified.
The genetic makeup of B.burgdorferi consists o f a 1000 kilobase chromosome
and has a cytosine/guanine ratio o f 27 to 30%. In addition to the chromosome, four to
nine circular and linear plasmids (linear plasmids are unique to the genus Borrelia)
ranging in size between 16- to 175-kilo bases have been identified in isolates o f
B.burgdorferi (49,65,118,119). The spirochetes are clonal and show no evidence of
lateral gene transfer between organisms (91). Therefore, all genes within a strain will
share a common evolutionary history in the absence of recombination. In addition, no
antigenic variation involving altered expression of proteins by genetic modification,
conferring a selective advantage to the organism has been documented for
B.burgdorferi. Fifteen other Borrerlia species, such as Borrelia hermsii the causative
agent of relapsing fever, exhibit antigenic variation by changing the expression of
immunodominant, surface exposed, lipoproteins known as Variable Major Proteins or
VMP (77). The genetic switch occurs between two linear plasmids, one carrying the
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silent VMP gene and the other carrying the expressed VMP gene proceeded by a
promoter. The silent gene physically replaces the active gene during genetic
recombination, and the formerly active gene is lost. Borrelia burgdorferi's close
relation to these organisms, and possession of linear plasmids, led researchers to
investigate antigenic variation in the Lyme disease spirochete. Initially data regarding
the discrepancy between protein profiles and antigenicity of spirochetes recovered from
inoculated hosts versus the profiles of the original inoculum (usually an uncloned
population) was misinterpreted as possible antigenic variation (77,104). However,
subsequent analysis using cloned organisms revealed the inaccuracy of the conclusion.

F. Discovery of P39
P39 was initially described in an attempt to identify B.burgdorferi specific
antigens that could enhance the specificity of diagnostic assays. P39 was shown to be
consistently immunogenic in experimentally and naturally infected mice (24,74) and
one hundred percent (n=94) o f confirmed Lyme patients tested produced antibodies
specific for P39 (74). More importantly, no anti-P39 antibodies were found in control
sera collected from 25 patients with other spirochetal illnesses such as syphilis, and
relapsing fever, or amyotrophic lateral sclerosis (an auto immune disorder) or normal
individuals (74). It was also demonstrated that P39 expression is conserved among
North American and European isolates (24), a trait not shared by several other
B.burgdorferi proteins such as OspA, OspB, and OspC (103, 104). As a result, the
immunogenicity, species specificity, and conserved expression of P39 have made it an
indispensable tool for the diagnosis Lyme disease. Currently microtiter plates coated
with E.coli expressing recombinant P39 are used in screening o f sera for Lyme disease
(General Biometrics, SanDiego, CA). Purification of P39 does not enhance the
effectiveness of this assay, therefore the Ecoli expressing P39 is used.
Two different monoclonals were developed for further study of P39. The first
monoclonal was developed using recombinant P39 antigen. The gene encoding P39
was cloned in a pBluescript vector designated pSPR33. This recombinant P39 antigen
was expressed in E.coli and was injected into Balb/c mice. The monoclonal antibody
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D1C9 was obtained from this experiment and subsequently shown to be specific for
B. burgdorferi P39 antigen by western blot analysis (24,74). The epitope for DIC9 has
not yet been mapped, but the monoclonal has a high titer and is commonly used in our
laboratory at a 1/250 or greater dilution for IFA or ELISA. Another monoclonal to
P39, Hkmy, was developed by injecting B. burgdorferi into mice and screening
hybridomas for reactivity to P39. However this monoclonal is o f very low titer and
must be used undiluted. This monoclonal was not used in the present study due to the
weak reactivity to P39. Accurate detection and quantitation of P39 was necessary for
this study and the weak reactivity o f this antibody would not allow such analysis.
The location and function of P39 within the organism is unknown. However, a
sequence analysis of the cloned P39 gene revealed the coding sequence to be 1020
nucleotides in length (112) and the deduced amino acid sequence has the highest
homology (27%) with TmpC, a putative membrane protein of the spirochete
Treponema pallidum (112) also o f an unknown function. The amino terminus of P39
contains charged residues followed by hydrophobic residues consistent with a signal
peptide sequence, and the amino acids from residues 14-18 are consistent with a signal
peptidase H site (112). These observations suggest that P39 may be associated with
either the outer membrane or the inner membrane of B. burgdorferi (112). A study
attempting to locate P39 in whole cell Borrelia using immuno-electron microscopy
(EM) with monoclonal antibody Hkmy gave some evidence for membrane as well as
cytoplasmic localization (120). However, most EM studies of P39 have been
unsuccessful (this lab, Schwan unpublished data) making confirmation of this finding
difficult.

G. Focus of the present study
1. Rational
P39 is an important molecule in respect to the diagnosis of Lyme disease, yet
little is currently known about the molecule. For instance where it resides, what it
associates with in the cell, and if it is related to the infectivity of the organism, or a
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cause in the pathology of Lyme disease are all unknown. The objective o f the present
study is to more fully understand the physical and biochemical nature o f the P39
molecule expressed by B.burgdotferi. If the molecules responsible for B.burgdorferi
infectivity or pathology in Lyme disease are elucidated, more effective treatments and
therapies for Lyme disease patients would be forthcoming.

2. Specific Aims
1. The first objective was to determine where P39 resides within infectious and
noninfectious spirochetes and determine if there is a correlation between P39
localization and infectivity. Whole cell spirochetes were separated into three
subcellular fractions: outer envelope, innermembrane, and cytosolic fractions. Cell
fractions were analyzed by SDS-PAGE, silver stain and western blot to determine the
protein composition o f each fraction. This procedure was performed on both infectious
and noninfectious isolates, allowing for correlation between P39 localization and
infectivity of the organism.
2. The next aim was to determine if P39 surface expression was uniform
throughout a population of spirochetes. Since several of the isolates used in the study
were uncloned populations, it was important to determine the variability in P39 surface
expression within an isolate. Both cloned and uncloned populations of B.burgdorferi
were analyzed by flow cytometry after staining with a monoclonal specific for P39.
3. The next aim was to determine the solubility of P39 and determine if the
solubility of P39 differed in infectious and noninfectious isolates. Detergent extraction
techniques were employed to separate hydrophobic and hydrophilic components of cell
fractions from infectious and noninfectious isolates, and they were analyzed by SDSPAGE and western blot.
4. The next aim was to determine what molecules associate with P39, and if
those molecules are different in infectious and noninfectious isolates. Whole cell
sonicates were subjected to immunoprecipitatioh using a monoclonal specific for P39.
The immunoprecipitants from infectious and noninfectious isolates were then analyzed
by SDS-PAGE and silver staining.
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5.

The final aim was to assess the role o f P39 in the infectivity o f the spirochete

and in the pathology o f Lyme disease. The cloned P39 gene was mutated by deletion
o f a 300 bp fragment from the front of the reading frame. The resulting mutant P39
gene was used to transform low passage infectious organisms in order to create
B.burgdorferi P39-less mutants. Using this approach, one can specifically determine if
expression of P39 is required for B.burgdorferi viability, infectivity, or if P39 is
involved in the pathology of Lyme disease.
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LI. MATERIALS AND METHODS

A. Materials
1. Borrelia isolates
Characteristics of P39 (localization, etc.) were investigated by comparing
various infectious and noninfectious isolates of B.burgdorferi. All isolates used in this
study are members of the group B.burgdorferi sensu stricto originally isolated from
Ixodes scapularis ticks (4). Isolate CN40 is a clonal population derived from isolate
N40 after the fourth in vitro passage (62). N40 was originally isolated in 1988 from a
tick in Westchester County, New York (121). CN40 is the only population of
B.burgdorferi known to retain infectivity during in vitro culture. This isolate allows
observation of changes in B.burgdorferi which are due to in vitro culture and not
related to loss of infectivity. CN40 was kindly provided by Dr. Stephen Barthold (Yale
University, New Haven, CT).
All remaining isolates are uncloned populations, and serve as model isolates
which lose infectivity after in vitro culture. These isolates include B31, WCH1, and
JD1. Isolate B31 (purchased from American Type Tissue Culture Collection ATCC
35210) is the prototype B.burgdorferi isolate, and was recovered from a pool of adult
Ixodes scapularis from Shelter Island, NY by Willy Burgdorfer in 1982 (4). Isolate
WCH1 was isolated from adult Ixodes scapularis ticks from Westchester County, N Y
in 1986. Isolate JD1 was isolated from nymphal Ixodes scapularis ticks collected in
Ipswich, MA in 1987 (53). Both JD1 and WCH1 were a gift from Dr. Joseph Piesman
(Center for DiseasfrControl, Fort Collins, CO) for use in this study.
Nine additional clones were generated from WCH1 by the author by limiting
dilution, and analyzed by flow ctytometry (see below).
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2. Ticks
Laboratory raised, spirochete-free Ixodes scapularis nymphal ticks were a gift
from Dr. Joseph Piesman (Center for Disease Control, Fort Collins, CO), and were kept
in mesh covered glass vials and placed in a climate controlled incubator (26°C ±
l°)with 92 ± 2% relative humidity and 14:10 light dark cycle.
3. Mice
Six to 12 week old, female B6CBAF1/J mice (Jackson Laboratory, Bar Harbor,
ME) were used for the infectivity assay. Prior to the assay, daily care for the animals
were provided by the Animal Facility at Old Dominion University. All treatment of
the animals was approved by the University LACUC and was in accordance with the
Federal Guide for the Care and Use of Laboratory Animals.
4. Medium
Borrelia burgdorferi isolates were cultured in liquid BSKII or BSKH medium
supplemented with 6% rabbit serum (Pel Freeze Biologicals, Rogers, Arkansas) and
antibiotics (phosphomycin 100 mg/ml and rifampicin 50 mg/ml, SIGMA chemical
company, St. Louis, MO). For infectivity studies cultures were grown in 15 ml screw
cap vials, and for fractionation studies isolates were grown in three 30 ml culture
flasks.
5. Monoclonal antibodies
Monoclonal antibodies (Mab) used in this study were as follows: Mab D1C9,
specific for P39 was provided by Dr. Tom Schwan (Rocky Mountain Laboratories,
National Institute o f Allergy and Infectious Diseases, Hamilton, MT). Mab H5332
specific for OspA, Mab H6831 specific for OspB, Mab H9724 specific for flagellin,
and H4825 specific for B.hermsii were provided by Allen G. Barbour (Health Science
Center, Univ. of Texas, San Antonio, TX). Goat anti-mouse IgG fluoresceinisothiocyanate conjugate (FITC) was purchased from Kirkegaard Perry Labs,
Gaithersberg, MD, as well as peroxidase labeled goat anti-mouse IgG.
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6. Plasmids
a. pSPR33
The pBluescript plasmid pSPR33 contains an 6.3 kb insert encoding P39 and a
second open reading frame (ORF2) (24, 74). The plasmid was given to this lab in a
glycerol stock by Dr. Tom Schwan (Rocky Mountain Laboratories, National Institute
of Allergy and Infectious Diseases, Hamilton, MT).

b. pCHHO
The plasmid pCHl 10 contains an insert (3.6 kb) encoding the entire Beta
galactosidase gene (LacZ). LacZ metabolizes B-galactose into glucose and lactose
molecules. The plasmid was given to this lab by Dr. Timothy Bos (Eastern Virginia
Medical School, Norfolk, VA).
7. PCR Prim ers
The primer sequences were derived from a randomly cloned, chromosomal
DNA of isolate B31. The sequence is specific for B.burgdorferi and is not present in
other Borrelia species (122, 123,124,125). Initially described by Rosa and Schwan
(123,125), this genomic sequence has been analyzed by several databases and no
homology has been found between the deduced amino acid sequence and any known
proteins. Regardless, the value of this sequence lies in its conservation among
B.burgdorferi and its absence in other Borrelia species. In addition, it is a
chromosomally located gene sequence as opposed to a plasmid encoded gene; this is an
important feature since plasmids are heterogenous among isolates and can be lost
during in vitro culture.

Forward primer sequence:

CGAAGATACTAAATCTGT

Reverse primer sequence:

GATCAAATATTTCAGCTT
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The primers were synthesized at the Core Molecular Biology facility at Eastern
Virginia Medical School.

8. Buffers
Sodium bicarbonate buffer: 14 mM Na2C 03, 34 mM NaHC03, pH=9.6
Phosphate buffered saline (TBS): 10 mM NaCL, 8 mM Na2H P04, 8 mM NaH2P 0 4
pH=7.4
PBS-Tween: PBS supplemented with 0.05% Tween 20 detergent (Sigma).
PBS-Tween/BSA: PBS-Tween supplemented with 1 mg/ml Bovine Serum Albumin
(BSA, Sigma).
PBS/MeCl?: PBS supplemented with 5 mM MgCl2 pH=7.8
Ketamine/xvlazine solution: xylazine 20 mg/ml (Butler, Columbus, OH) and ketamine
62.5 mg/ml (Aveco Co., Fort Dodge, IA)
Lysis buffer: PBS, 1% SDS, and 0.1 mM proteinase K
2x sample buffer: 1.25 mM Tris[hydroxymethyl]amino-methane (Tris), 20% glycerol,
4% SDS, 10% 2-mercaptoethanol, H20, pH=6.8
Coomasie fixing solution: 40% methanol, 10% acetic acid, 0.5% coomasie brilliant
blue
Destaining solution: 40% methanol, 10% acetic acid solution
Silver equilibration solution: 0.5% silver nitrate in water
Development solution: 10% sodium carbonate,-0.05% formaldehyde in water
Stop solution:!% glacial acetic acid in water
Reducer solution: 0.6% Potassium ferricyanide, 1.3% Sodium thiosulfate, 0.2%
Sodium carbonate
Electroporation solution fEPSk 272 mM sucrose and 15% glycerol.
TE buffer: 50 mM Tris, 50 mM EDTA, pH=8.0
10x blunt end buffer: 100 mM Tris pH=7.5,0.5 mM EDTA, 50 mM MgCl2
NET buffer: 150 mM NaCl, 5 mM EDTA, 50 mM Tris pH=7.5,0.05% NP-40
Resuspension Buffer P 1: 100 pg/ml RNase A, 50 mM Tris/HCL, 10 mM EDTA,
pH=8.0
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Lvsis Buffer P2: 200 mM NaOH, 1% SDS
Neutralization Buffer P3: 3.0 M potassium acetate KOac, pH=5.5
Equilibration Buffer OBT: 750 mM NaCL, 50 mM MOPS, 15% ethanol, pH=7.0,
0.15% Triton X-100
Wash BufferOC: 1.0 M NaCL, 50 mM MOPS, 15% ethanol, pH=7.0
Elution Buffer OF: 1.25 M NaCl, 50 mM Tris/HCL, 15% ethanol, pH=8.5

B. Methods
1. Establishment of infectious and noninfectious populations of Borrelia
burgdorferi
Noninfectious isolates were generated from infectious WCH1 passage 5 (p5),
JD1 passage 3 (p3), and B31 passage 6 (p6) by culturing each in vitro for
approximately 3 months. The Borrelia were grown in screw cap vials with 15 ml of
BSKII incubated at 33°C, and were passed once a week by transferring 5% of spent
culture to a new tube o f fresh media (equivalent to one passage). Isolates were
routinely analyzed by dark field microscopy and motility, activity, and general
appearance were noted. An isolate was designated high passage after passage 15.
Passage fifteen was considered a sufficient end point for high passage since most
isolates lose infectivity by the tenth passage. In this study, isolate CN40 was cultured
as described above and harvested at p9 and p22 . Isolate CN40 is unique in its ability
to retain infectivity during in vitro culture and was used in this study as a control for
changes induced by in vitro culture which have no affect on infectivity. All isolates
were counted using Petroff-Hauser bacterial counting chamber (Baxter Scientific,
McGaw Park, 111.). Each isolate was counted three times and the values averaged. The
averaged value was recorded as the concentration of spirochetes in culture.
The method used to assess infectivity of B.burgdorferi has been previously
described (7,67,68). Briefly, low passage (p< 10) and high passage (p>15) isolates
were harvested by centrifugation at 10,000 x g for 10 min at 4°C. Spent media was
decanted and cells were washed to remove all traces of media by resuspending the cell
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pellet in 10 ml o f PBS/MgCl2 and repeating the centrifugation step. This washing step
was repeated once more and the final cell pellet was resuspended in 5 ml of
PBS/MgCl2 The Borrelia were counted on a Petroff -Hauser chamber and adjusted to
106 organisms per ml. Viability o f washed organisms was confirmed by re-inoculation
of 20 pi into 2 ml o f BSK II media.
For each isolate, two B6CBAF1/J mice received an intraperitoneal (i.p.)
injection o f 100,000 spirochetes. After 15 days, mice were sedated with a 50 pi
injection o f ketamine/xylazine solution, and 25 Lscapularis nymphs were allowed to
feed on the mice for xenodiagnosis. Mice were then placed in individual chambers
with wire mesh flooring. The chambers were elevated over collecting trays lined with
double sided tape which served to retain the ticks once they detached from the mice
after feeding. The mice were kept in these cages for five days. The engorged nymphs
were collected and kept in glass vials for 6 days at room temperature to allow Borrelia
to multiply. Using a sterile razor blade, ticks were dissected and gut contents were
smeared onto a glass slide and processed by immunofluorescent antibody assay (IFA)
for detection o f Borrelia as described below.
Mice were sacrificed by cervical dislocation 21 days post-inoculation and the
bladders were surgically removed and divided into two equal halves. One half was
cultured in BSK-II media (tissue culture) and the other half was frozen in BSK II media
at -80°C until needed for further analysis by PCR as described below. An isolate was
considered infectious if spirochetes were recovered from mouse tissue, detected in tick
smears, or detected by PCR in tissue samples. All negative results were confirmed by
repeating the experiment.
For tissue culture, one half of a mouse bladder was placed in an eppendorf tube
containing 500 ul BSK II media. The tissue was mascerated for one minute using a
sterile pestle. The mascerated tissue and media was divided into two aliquots and each
aliquot was added to a 10 ml tube o f BSK II. Cultures were incubated at 33°C, and
were viewed by dark field microscopy every 3-4 days for detection o f B.burgdorferi.
The presence of the spirochete was confirmed by immunofluorescence assay as
described below.
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a. Immunofluorescence assay (IFA)
Culture supernatants (20 pi) or tick guts (each tick analyzed individually) were
smeared onto glass slides, air dried for 10 minutes, then fixed with acetone
(Mallinckrodt Inc., Paris, KY) for 20 minutes at room temperature. The slides were
rinsed 3 times in PBS and 10 pi o f undiluted monoclonal antibody (Mab) H5332
specific for B.burgdorferi outer surface protein A (OspA) was added to each slide and
incubated for 1 hour in a humid, dark chamber at 37°C. The slides were rinsed 3 times
in PBS and 10 ul of goat anti-mouse IgG fluorescein-isothiocyanate conjugate (1/40 in
PBS) was added to each slide and incubated for. 1 hour at 37°C in a humid, dark
chamber. The slides were rinsed 3 times in PBS and frozen at -20°C until viewed by
fluorescence microscopy using an Olympus AH-2, Vanox model T microscope.
OspA was selected as the target antigen due to the high surface expression of
this antigen in all the isolates used in this study (53,126). IFA staining of OspA gives
very high fluorescence and is readily detectable. Other antigens, such as P39, are not
readily detectable by IFA presumably because the epitope is fixative sensitive.
Fluorescent intensity was monitored and given a rating: - (no fluorescence) or +
(fluorescence equivalent to a positive control slide containing B31 spirochetes). Tissue
cultures were designated positive if one or more spirochetes were detected by IFA, and
negative if no spirochetes were detected by IFA.

b. Polymerase chain reaction (PCR)
PCR was used to detect B.burgdorferi DNA in bladder tissue samples taken
from mice using methods previously described (122,123,124,125). Frozen tissues
(one half of the total organ) were thawed at room temperature then rinsed in sterile PBS
and minced with a sterile scalpel. The minced tissues were suspended in 1 ml of lysis
buffer and incubated at 37°C for 24 hr. Samples were then extracted twice with 1:1
volume of phenol/chloroform followed by a final 1:1 chloroform extraction. The DNA
was precipitated by the addition o f 1 ml of ice cold 100% ethanol and 10 pi of 3M
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sodium acetate. The samples were incubated at -20°C overnight and DNA was
pelleted by centrifugation at 14,000 rpm for 15 min at 4°C. The pellets were air dried
and resuspended in 50 pi sterile water. Samples were heated to 100°C for 5 min to
inactivate proteinase K. The DNA concentration was determined by OD 260. Each
PCR reaction contained 500 ng of template DNA, 5 pi o f each primer (10 pM), 10 pi
o f dNTP (1.25 mM), 1 pi o f Taq polymerase, 10 pi of lOx PCR buffer, and a final
magnesium concentration o f 1.5 mM in a 100 pi volume. Controls included the
following: a water control for PCR contamination, 500 ng of DNA extracted from
uninfected mouse tissue spiked with lpg, 10 ng, or 10 pg of B.burgdorferi template
DNA. After an initial 5 min denaturing step at 94°C, 30 cycles were executed as
follows: denature 1 min at 94°C, anneal 30 sec at 37°C, and extension 2 min at 72°.
PCR was performed on an automated thermal cycler (Perkin Elmer). Ten microliters
o f each PCR reaction was electrophoresed on a 0.8% agarose gel followed by staining
with ethidium bromide to detect DNA bands.

2. Protein localization in B.burgdorferi
a. Cell fractionation of Borrelia burgdorferi
Spirochetes were collected from culture by centrifugation at 10,000 x g at 4°C
for 10 min and adjusted to 35 x 106 organisms/ml in PBS. Spirochetes were not
washed further due to the fragile nature o f the outer envelope (127). The outer
envelope was removed by adding sodium dodecyl sulfate (SDS) to a final
concentration o f 0.03% in a 10 ml volume of spirochetes, followed by incubation at
room for 15 min. During this step the outer envelope is solublized and remains in the
aqueous phase. The solution was centrifuged at 15,000 x g for 90 min to pellet the
intact protoplasmic cylinders (intact cell without outer envelope). The supernatant
containing the outer envelope fraction (OE) was removed and the protoplasmic
cylinders were resuspended to the original volume in PBS thereby retaining equivalent
concentration of spirochetes. The protoplasmic cylinders were then sonicated on ice
for 3 minutes in 20 second pulses to break apart the cell. The sonicate was centrifuged
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for two hours at 138,000 x g at 4°C to separate the inner membrane fraction and the
cytosolic fraction (pellet and supernatant respectively). The cytosolic fraction (CY)
was removed and the inner membrane fraction (IM) was resuspended in PBS to
original volume to maintain equivalence. All fractions were stored at -20°C. A media
sample was run through the fractionation procedure and 8 ul were included on gels
developed by silver staining (media control).

b. Protein assay of cell fractions
The protein concentration o f each cell fraction was determined using Micro
BCA Protein Assay Kit (Pierce, Rockford, IL ). Standards were tested in duplicate at
the following concentrations: 0.5, 1 ,2 ,4 ,8 ,1 2 ,1 6 , and 20 |ig/ml. Each sample was
tested in triplicate at the following volumes: 5 ul of outer envelope, 10 ul o f inner
membrane, and 20 ul of cytosolic fraction. Due to the low protein content o f the inner
membrane and cytosolic fractions, a larger sample size was needed to assess the protein
concentration within the range of the assay (0.5 ug/ml).

c. SDS-PAGE
All reagents were prepared according to the method of Laemmli (128). The cell
fractions collected from isolates were subjected to SDS-PAGE. Equal volumes (8
microliters) o f each cell fraction (OE, IM, CY), representing material derived from 107
organisms, were added to 20 microliters of 2x sample buffer. The samples were boiled
for 1 min then loaded onto a SDS-PAGE 12-15% gradient gel and electrophoresed at
250 volts for approximately 3.5 hours. Gels were then processed by silver staining or
western blot as described below.

d. Western Blot
The electrophoresed proteins were transferred to 0.22 micron nitrocellulose
paper (Micron Separations Inc., Westboro, MA) via western blot at 14 volts overnight.
The blot was soaked for 1 hour in 1/20 milk diluent (KPL) in PBS-Tween 20.
Spirochetal antigens (P39, Osp B, Osp A, and flagellin) were detected using the

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

26
following monoclonal antibodies: D1C9 (anti-P39,1/250), H6831 (anti-OspB, 1/1500),
H5332 (anti-OspA, 1/2000), H9724 (anti-Fla, 1/100). Blots were incubated with the
monoclonal antibodies for 1 hour on a rotating plate. The blots were rinsed 4 times
with PBS/Tween 20, then incubated with a 1/2000 dilution of goat anti-mouse IgG
peroxidase (KPL) conjugate for 1 hour on a rotating plate, followed by four successive
washes with PBS/Tween 20. Blots were developed with TMB peroxidase substrate
(KPL) for 5-10 min followed by one thorough wash with distilled water to stop the
reaction. Blots were scanned by a LKB 2222-20 Ultroscan laser densitometer
(Pharmacia, Bromma, Sweden) for quantitation o f reactive proteins in each fraction.
Data was analyzed by regression analysis.

e. Silver Stain
Gels were silver stained using Sigma’s Silver Stain Kit AG-25 as directed by
the manufacturer. Gels were placed in 300 ml o f silver equilibration solution for 30
min with constant agitation. The silver solution was discarded and the gels quickly
rinsed in water for 10-20 seconds. Developer solution was then added to the gels in
two successive washes o f 150 ml each. The development of bands was aborted by
washing the gels in Stop solution for 5 min, followed by three washes in water for 10
min each. Gels were then placed for 20 seconds in 300 ml of Reducer solution in order
to reduce background staining. Gels were subsequently washed three times in water
for 10 min each rinse. Gels were then photographed for preservation of the data.
According to the manufacturer, silver staining can detect as little as 50 ng of protein,
but the intensity o f staining depends upon the characteristics of each individual protein
(129,130).
3. Flow Cytom etry

a. Generation of clonal populations of WCHI
Clones o f isolate WCHI p5 were generated by limiting dilution (131). Cells
were counted using a Petrof-Hauser chamber, and one ml of culture was serial diluted
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10-fold in BSK II media until a concentration o f approximately one B.burgdorferilxal
was obtained. Fifty cultures (one ml each) were grown as described above and checked
every week using dark field microscopy for detection o f B.burgdorferi. A total of nine
clones were obtained from the 50 cultures. Clones were designated WCHI clone 1,
clone 2, etc. through clone 9 and were harvested at p6 and p i 7. Clone 4,7, and 8 were
discarded because o f fungal contamination.
The remaining clones were analyzed by ELISA for differences in P39
expression using the following procedure: Whole cell antigen was prepared by
harvesting organisms from a 30 ml culture (passage 6) by centrifugation at 10,000 x g
for 10 min and adjusting in PBS to a cell density of 0.25 OD at 650 nm (approximately
106 org./ml). Sonicated antigen o f these six clones was prepared by sonicating on ice
one ml of whole cell suspension four times for 30 seconds at 30 W (Sonifier cell
disrupter, Branson Sonic Cc., Danbury, CN). Whole cell and sonicate preparations of
WCHI p.5, and WCHI clones at p.6 were plated in duplicate on 96 well microtiter
plates (Falcon 3911 assay plates, Becton, Dickinson Labware, Oxnard, CA) using
sodium bicarbonate buffer. The final volume in each well was 100 ul. Plates were
covered with saran wrap and stored at 4°C overnight. Plates were washed three times
in PBS-Tween. Each well was blocked using PBS-Tween/BSA at a final volume of
100 ul/well. Plates were incubated with constant agitation 0.5 hour. Plates were
washed three times in PBS-Tween. Antigen was detected using Mab D1C9 (specific
for P39) at 1/1000 in PBS-Tween/BSA. Plates were incubated with constant agitation
for 0.5 hour, then washed three times in PBS-Tween. Bound antibody was detected
using peroxidase conjugated Goat anti-Mouse IgG at 1/800 in PBS-Tween. Plates
were incubated with constant agitation for 0.5 hour. Plates were washed three times in
PBS-Tween. TMB Peroxidase substrate (KPL) was added at a final volume o f 100
ul/well. After five minutes, plates were read on a spectrophotometer at 650 nm. Two
wells containing no antigen were included on each plate. The readings obtained in
these two “blank” wells were averaged and this value, designated nonspecific
reactivity, was subtracted from the values obtained for whole cell and sonicate antigen.
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The adjusted values of each duplicate sample was then averaged and used as the final
value o f absorbance at 650 nm. Interassay sample variation was less than 0.2 units of
absorbance.

b. Flow cytometry analysis of cloned and uncloned B.burgdorferi
Whole cells were assayed by flow cytometry to determine if outer surface
expression o f P39, OspB, and OspA were uniform among cloned, uncloned, infectious,
and noninfectious populations o f B.burgdorferi. Two hundred microliters of
uncloned, whole cell WCHI, JD1, and B31, as well as the cloned populations of CN40,
and WCHI clone 1 were incubated with 20 ul of undiluted anti-OspA, anti-OspB, antiFla, or anti-P39 for 30 min at room temp. Cell were pelleted by centrifugation at
14,000 rpm for 1 min, the supernatant was aspirated, and the pellet resuspended in 200
ul of PBS. Five microliters o f goat anti-mouse IgG fluorescein-isothiocyanate
conjugate (1/40 in PBS) was added to each sample. All samples were covered with foil
to protect from the light. Samples were incubated for 30 min at room temp, washed
twice in PBS, then resuspended to 500 ul. PBS. Samples were filtered through a 0.44
micron filter to remove any particulate debris, then read on a FACScan single laser
flow cytometer (Becton Dickinson, Mountain View, CA). Settings were as follows:
0.250mW at 430 volts, 5000 organisms read for each sample. The control for
nonspecific staining was B31 incubated without primary antibody, but with the
secondary antibody.

4. Triton X-114 phase partitioning of hydrophobic proteins
Triton X-l 14 phase partitioning of Borrelia proteins (132,133,134,135) was
performed in order to determine the soluble character of P39. Two hundred microliters
of whole cell sonicate or cell fractions from CN40 or B31 were mixed with 600 ml of
TE buffer and Triton X-l 14 (SIGMA) was added to a final concentration of 1%. The
samples were placed on ice for 15 minutes and inverted occasionally. The samples
were then warmed to 36°C for 5 min. When the solutions became cloudy, the samples
were centrifuged at 2,500 rpm for 3 min in order to separate the phases. The aqueous
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phase was transferred to a new tube. All detergent soluble phases were washed three
times by resuspension in TE and Triton X-l 14 (final concentration of 1%), followed by
incubation on ice for 15 min, incubation at 36°C for 5 min, and centrifugation.
Aqueous phases were washed 3 times by adding Triton X-l 14 to a final concentration
o f 2% (to ensure complete removal o f hydrophobic molecules), followed by incubation
on ice for 15 min, incubation at 36°C for 5 min, and centrifugation. The final aqueous
and detergent soluble fractions were then acetone precipitated with 2 volumes of cold
acetone and incubated overnight at 4°C. The samples were centrifuged at 14,000 rpm
for 10 min at 4°C. The pellets were air dried for 20 min and resuspended in 100 ml of
lx Laemmli sample buffer. Prior to loading onto a SDS-PAGE, the samples were
boiled for 5 min then centrifuged for 1 min at 10,000 rpm to pellet any insoluble
material. Thirty microliters were loaded onto a 12.5% gel.. Electrophoresis was
conducted for 3 hours at 250 volts. The gels were subjected to western blot and
developed using antibody D1C9 specific for P39 as described previously.

5. Immunoprecipitation
Immunoprecipitation of P39 from whole cell sonicates of infectious and
noninfectious spirochetes was performed. Two hundred microliters (approximately 7 x
106 organisms) o f whole cell sonicate were precleared by adding 450 ml o f NET
buffer, 1 mg/ml BSA, and 50 pi of prewashed Pansorbin. The mixture was incubated
for 1 hr at 22°C, followed by centrifugation at 10,000 x g for 1 min. The supernatant
was removed and placed in a clean eppendorf tube. Ten microliters of monoclonal
antibody D1C9 (specific for P39), or an isotype matched control, Mab H4825 specific
for a Borrelia hermsii antigen (104), was added to each tube and incubated at 22°C for
1 hr. Seventy five microliters of prewashed Pansorbin was added and the mixture was
incubated for 10 min at 22°C. The Pansorbin was collected by centrifugation for 1 min
at 10,000 x g. The samples were washed three times in 750 pi of NET buffer. The
final pellet was resuspended in 50 pi o f sample buffer and boiled for 5 min. Samples
were centrifuged at 3,000 x g to pellet insoluble material, and the supernatant was
loaded onto 12.5% SDS-PAGE gel. Gels were electrophoresed for 3.5 hr at 250 volts
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and subsequently silver stained. Immunoprecipitation was also attempted with
ZYMED (recombinant protein A-sepharose 4B conjugate, ZYMED Laboratories, Inc.,
San Francisco, CA), but high background and low recovery of P39 were found to occur
with this product and therefore was not used in this study.
6. Genetic manipulation of the cloned P39 gene
To determine if P39 expression in B.burgdorferi is required for the infectivity
o f the organism, or involved in the pathology in Lyme disease an attempt was made to
inactivate the P39 gene in the spirochete. Two strategies were employed to inactivate
the endogenous P39 gene: first, a P39-LacZ gene fusion, and second, a P39 deletion
mutant construct.
a. Attempts to construct a P39-LacZ fusion gene
A unique restriction site Bsu36I was detected 90 nucleotides 3’ of the start codon o f
P39 (Appendix 1). This site was selected as the insertion point for the LacZ gene.
The proximity to the start site ensures no functional P39 activity will exist in the P39
lacZ fusion. The lacZ gene already contains a Bsu36I site at the 5’ end of the gene but
does not contain a Bsu36I site at the 3’ end o f the gene (Appendix 2). Two different
strategies were employed for creating a 3’ sticky end compatible with the P39 Bsu36I
site. The first approach required using oligo linkers to insert a new Bsu36I site within
the BamHI site 3’ of LacZ gene. The second strategy utilized a Mael site (sequence
compatible sticky end) 3’ of the LacZ gene instead o f creating a new Bsu36I site.
(1). Plasmid pSPR33
The plasmid pSPR33, encoding P39, was given to this lab in a glycerol stock of
JM109 Kcoli cells. A sample from the glycerol stock was streaked onto a LB agar
plate containing 200 mg/ml ampicillin (LB/Amp). Plates were incubated overnight at
37°C. One colony was selected from the plate, inoculated into 5 ml of LB/Amp media,
and incubated overnight at 37°C with constant rotation. For large scale production of
the plasmid, 150 ml o f LB/Amp was inoculated with 1.5 ml o f overnight culture, and
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incubated overnight at 37°C with constant rotation. The culture was harvested the next
day by centrifugation at 14,000 rpm x 2 min x 4°C. Purified plasmid was collected
from the culture using QIAGEN midi kit as directed by the manufacturer (QIAGEN
Inc., Chatsworth, CA). The directions for the midi prep are shown below. The cell
pellet was resuspended in 4 ml o f Resuspension Buffer PI. Four ml o f Lysis Buffer
P2 are added, mixed gently by inversion of tube, and incubated at room temp for 5 min.
Four ml o f Neutralization Buffer P3 are added and mixed immediately by inversion of
the tube, and incubated on ice for 15 min. The samples are then centrifuged for 30
min. at 30,000 x g at 4°C. The supernatant is removed promptly and is passed over an
equilibrated QIAGEN column (previously washed with Equilibration Buffer QBT)
which acts to retain the plasmids. The column is then washed twice with 10 ml of
Wash Buffer QC. This removes all nonspecifically bound molecules from the column.
The plasmid prep is then eluted off of the column with 5 ml of Elution Buffer QF.
The eluate, containing the plasmid prep, is collected in a clean tube. The plasmid DNA
is then precipitated with 0.7 volumes of room temperature isopropanol, and centrifuged
immediately at 15,000 x g at 4°C for 30 min. The supernatant is carefully removed.
The pellet, containing plasmid DNA, is washed with 5 ml of cold 70% EtOH. The
pellet is then air dried, and resuspended in 100 ml o f sterile distilled H20 (dHOH). The
DNA concentration is determined by absorbance at 260nm on a UV
spectrophotometer.

(2). plasmid pCHHO
The plasmid pCHl 10 (encoding LacZ) was given to this lab as a glycerol stock.
A sample from the glycerol stock was streaked onto a Luria broth (LB) agar plate
containing 200 pg/ml ampicillin (LB/Amp). Plates were incubated overnight at 37°C.
One positive colony was selected and a plasmid prep was prepared as described above.

(3). Creating new Bsu36I site 3’ of LacZ gene
Ten micrograms of pCHl 10 was digested with BamHI, and the digested DNA
was purified on a 5% acrylamide gel, electroeluted and ethanol precipitated as
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previously described. The ends o f the linearized pCHl 10 was dephosphorylated using
calf intestinal alkaline phosphatase treatment (CIAP, Promega). The purpose of CIAP
is to remove the phosphate group from the ends of the digested plasmid, thereby
preventing religation o f the plasmid in the absence of an insert. The DNA was then
purified using phenol chloroform extraction and ethanol precipitation. The
oligonucleotides (synthesized at the Core Molecular Biology Laboratory, EVMS)
encoding a new Bsu36I site were first annealed to each other prior to use in the ligation
with pCHl 10. The ligation was performed at three different ratios of vector and insert
DNA; 1:1,1:3, and 3:1. Ligation reactions were screened in JM109 E.coli Ampr.

(4). Using sequence compatible ends for insertion of LacZ into P39
Ten micrograms of unmodified pCHl 10 (Appendix 2) was digested with Bsu36I and
Mael. The digested DNA (pCHl 10*B*M) was electrophoresed on an agarose gel.
The insert was excised from the gel and electroeluted. The insert DNA was then
concentrated by ethanol precipitation. Ten micrograms o f PSPR33 was digested with
Bsu36I followed by CIAP. The digested DNA was purified as described above.
Ligation o f vector and insert DNA was performed at three different ratios 1:1,1:3, and
3:1. Ligation reactions were screened in JM109 E coli Ampr .

b. Attempts to construct a P39 deletion mutant
A 10 pg aliquot o f pSPR33 was digested with restriction enzymes Bsu361 and
Bal I (New England BioLabs). The digestion results in liberation o f a -300 base pair
fragment from the P39 open reading frame (approximately 300 bases 3’ of the start
site). To this reaction was added 1.5ml of Klenow fragment (3 units Boeringer
Manheim digitonin label kit), 2 ml of 0.5 mM dATP and 2 ml of 0.5 mM dTTP. This
mixture was incubated at 30°C for 15 min. The mixture was then heated to 75°C for
10 min to heat inactivate the enzymes. The DNA was purified by phenol extraction,
followed by ethanol precipitation. The DNA pellet was resuspended in 8 ml of water
and used in a ligation reaction with 1 ml of T4 DNA ligase, and 1 ml of 1Ox blunt end
buffer. The ligation reaction was incubated at 17°C for 5 hours. The ligation was
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screened in JM109 E.coli cells. E.coli cells were thawed on ice for 10 min and 40 ml
of cells are placed in a prechilled 0.2cm electroporation cuvette. Eight microliters of
ligation mix were added to the cuvette, and the cells were electroporated at 2.5 volts,
200 Ohms, 25mF. One ml o f S.O.C. medium was immediately added to the cuvette,
then transferred to a culture tube. The tube was incubated for 1 hour at 37°C with
constant rotation. Cells (200 pi) were streaked on LB/amp plates, and incubated at
37°C, overnight. Several colonies were selected, grown overnight in 5 ml o f LB/amp
broth, and were screened by Pst I digestion of miniplasmid preps. Colonies containing
the P39 deletion construct had digestion products migrating at 1.4kb, 3.5kb, and 4.5kb,
as compared to the wild type plasmid which had digestion products migrating at 1.7kb,
3.5kb, and 4.5kb. One positive colony (designated P39dm) was grown overnight in
150 ml of LB/amp, and the pSPR33 deletion-mutant plasmid collected with using a
QIAGEN prep kit as described above.

(1). Lack of P39 expression by P39 deletion mutant construct in E.coli
An aliquot of P39dm was harvested and washed three times in PBS to remove
all traces of media The cells were adjusted to 0.20 OD at 650 nm and subsequently
sonicated for one min on ice to break apart the cells. Two fold dilutions of P39dm
were plated on a microtiter plate in sodium bicarbonate buffer. Controls included
untransformed JM109 and JM109 expressing pSPR33 at the same concentration. All
samples were tested in triplicate. Plates were incubated overnight at 4°C and screened
by ELISA for P39 expression as described above.

c. Transformation of B.burgdorferi
The P39 deletion mutant construct was excised from the plasmid using Pst I
digestion. The digested plasmid was ethanol precipitated overnight. The digested
DNA was used to transform low passage infectious CN40. Spirochetes were collected
from mid-log phase culture, washed twice with cold PBS, and then washed three times
in cold EPS. The spirochetes were resuspended to a final concentration of 2 x 10s
cells/ml. Fifty microliters were transferred to a prechilled 0.2 cm electroporation
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cuvette along with 2 jag P39 deletion mutant DNA. One pulse was administered at
2.5kV, 25mF, 200 Ohms (Gene Pulser n, Bio Rad, Melville, NY) producing a time
constant o f 4-5 millisec. One ml o f BSK II medium with no antibiotics was added to
the cuvettte and transferred to 5 ml o f BSK II medium and incubated for 24 hours at
33°C.
The electroporated spirochetes were then screened by ELISA for expression of
flagellin (to confirm presence of spirochete) and loss of P39 expression (to confirm
transformation o f spirochete) using the following protocol. Twenty four hours after
electroporation, the spirochetes were counted on a Petroff-Hauser chamber. The
organisms were diluted in BSK II medium and plated out on 96 well tissue culture
plates at approximately one spirochete per well. The plates were incubated at 33°C for
10 days. A 50 ml aliquot was removed and saved from each well, then the original
plates were centrifuged at 3,000 rpm for 5 min to pellet the cells. Media was removed
from each well by aspiration. The cells were resuspended in 200 ml o f sodium
bicarbonate buffer. The solution was divided equally between two microtiter plates
(one hundred microliters per well) and both plates were incubated at 4°C overnight.
The plates were rinsed 3 times with PBS, and a 1/200 dilution of Mab D1C9 (specific
for P39) was added to one plate and a 1/100 dilution of Mab H9724 (specific for
flagellin). The plates were incubated at room temperature for 30 min with constant
rotation. The plates were washed 3 times with PBS, and bound antibody was detected
with a peroxidase conjugate (goat anti-mouse IgG) at 1/2000 dilution. The plates were
incubated at room temperature for 30 min with constant rotation. Plates were washed 3
times with PBS, and 100 ml o f peroxidase substrate (KPL) was added to each well.
Reactivity was detected on a spectrophotometer at 650 nm.
Flagellin reactivity was used to detect the wells containing spirochetes (as
opposed to being an empty well). P39 reactivity of each well was compared to that of
control wells containing unelectroporated B.burgdorferi. Readings which fell below (>
0.1 OD below control well) those obtained from the untransformed spirochetes was
considered a P3 9-low reading. This cut off level was selected in order to ensure all
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possible transformants would be detected. Samples that exhibited flagellin reactivity,
but were scored as low for P39 reactivity, were grown in culture for 10 days. These
cultures were subsequently examined by western blot to assess P39 expression in these
organisms.
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m . RESULTS

A. Establishment of infectious and noninfectious isolates of Borrelia burgdorferi
The infectivity of the low and high passage isolates, as defined by the ability to
survive in a host, was assessed in mice by needle inoculation. It was important to
confirm the infectivity status o f these isolates since the remainder of the study involves
comparison o f the infectious and noninfectious isolates. Accordingly, three separate
methods were used for verifying isolate infectivity: culture of mouse tissue,
xenodiagnosis using ticks, and finally PCR of mouse tissue. Low passage CN40 p9,
B31 p6, WCHI p6 and JD1 p3 and high passage CN40 p22 were all infectious based
on recovery o f spirochetes from mouse bladder tissue (Table 1). In contrast, the high
passage isolates B31 p.32, WCHI p. 15, and JD1 p. 15 were not recovered from mouse
tissue.
In addition, Borrelia were detected in ticks which fed on mice infected with
low passage WCHI and JD1 respectively (Table 1). No Borrelia were detected in ticks
which fed on mice inoculated with high passage WCHI and JD1.
The tissues from infected mice (inoculated with low passage B31, WCHI, JD1,
low and high passage CN40) were also positive for B.burgdorferi infection when
assayed by PCR using primers specific for B.burgdorferi chromosomal DNA (Fig. 1).
Tissues from noninfected mice (inoculated with high passage B31, WCHI, and JD1)
were not positive by PCR. Borrelia burgdorferi DNA was detected at a sensitivity of
10 pg o f spirochetal DNA (control lanes panel A, lane 9-12).
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Table 1. Infectivity of low and high passage Borrelia burgdorferi isolates.
Isolate

Passage

Tissue*

Tick”

PCR6

Infectivity0

CN40
CN40

9
22

2/2
2/2

nd
nd

2/2
nd

I
I

B31
B31

6
32

2/2
0/4

nd
nd

2/2
0/4

I
N

WCHI
WCHI

6
15

2/2
0/4

1/14
0/12

2/2
0/4

I
N

JD1
JD1

3
15

2/2
0/4

3/20
0/14

2/2
0/4

I
N

*Recovery of B.burgdorferi from cultured bladder tissues. Total number
positive/total number tested. All negative cultures were confirmed by repeating
the experiment.
bIFA detection of B.burgdorferi in ticks which had fed on inoculated mice. Total
number of positive ticks/total number of ticks tested. nd=experiment not done.
c Detection of B.burgdorferi DNA in mouse bladder tissue by PCR.
dInfectivity of B. burgdorferi isolate I=infectious, N=noninfectious.
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Figure 1. Detection of Borrelia burgdorferi DNA in mouse bladder tissue
using PCR. Template DNA was collected from mice inoculated with the
following low or high passage isolates: CN40 p.9 (panel A, lane 1 and 2), B31
p.6 (panel A, lane 3 and 4), B 31 p.32 (panel A, lanes 5-8), WCHI p.6 (panel
B, lane 1 and 2), WCHI p. 15 (panel B, lanes 3-6), JD1 p.3 (panel B, lane 7
and 8), JD1 p. 15 (panel B, lanes 9-12). DNA size markers are shown in lane
13 o f panel A and B. Control for PCR sensitivity shown in panel A: 500ng
of DNA extracted from uninfected mouse tissue was mixed with lug (lane 9),
lOng (lane 10), or 10 pg (lane 11) o f template B.burgdorferi DNA to
determine interference with PCR. A negative control is shown in A, lane 12.
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Based on these three separate criteria (tissue culture, xenodiagnosis, and PCR)
low passage CN40, B31, WCH1, JD1, and high passage CN40 were judged to be
infectious and high passage B31, WCH1, and JD1 were noninfectious. These
infectious and noninfectious organisms were next analyzed for P39, OspB, OspA, and
Fla localization within the spirochetal cell to determine if a correlation exists between
P39 localization and infectivity.

B. Subcellular localization and quantitation of P39, OspB, OspA, and Fla in
infectious and noninfectious isolates
1. Western blot of cell fractions
Infectious and noninfectious B.bvrgdorferi were separated into outer envelope,
inner membrane, and cytosolic fractions and analyzed by western blot /densitometry to
quantitate the antibody reactivity for each epitope (hereafter referred to as levels). The
P39, OspB, and OspA levels for infectious and noninfectious isolates were analyzed by
regression analysis to determine the statistical significance.

a. P39 levels
For all isolates, a decrease in P39 levels in the outer envelope correlated with
loss o f infectivity {P = 0.019) (Table 2). However, no significant interaction exists
between the amount o f P39 in the inner membrane (P = 0.24) or cytosolic fraction and
infectivity (P = 0.32).
There was considerable variability in P39 localization among isolates. Most
notably the P39 levels in the cloned, infectious isolate CN40 was located exclusively in
the outer envelope fraction. No P39 was detected in the inner membrane or cytosolic
fractions (Table 2, Fig. 2). Both outer envelope fractions of CN40 had comparable P39
levels, therefore P39 expression did not increase or decrease during in vitro culture.
In contrast, the P39 levels in the remaining uncloned isolates did change. For
B31, P39 was detected in all cell fractions, except infectious cytosol (Table 2, Fig. 3).
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Table 2. P39 levels in Borrelia burgdorferi cell fractions measured by
westernblot densitometry. ‘
Isolate

Infectivity

OE

IM

CY

Cumulative

CN40 (p5)
CN40 (p23)

I
I

0.639 ±0.10
0.727 ±0.11

0
0

0
0

0.639
0.727

B31
B31

I
N

0.187 ±0.11
0.467 ±0.14

0.124 ±0.10
0.171 ±0.07

0
1.09 ± 0.17

0.311
1.728

WCH1
WCH1

I
N

1.534 ±0.28
0.883 ±0.15

1.076 ±0.22
1.254 ±0.25

0.177 ±0.11
0.235 ± 0.15

2.787
2.372

JD1
JD1

I
N

1.154 ±0.14
0.713 ± 0.13

1.213 ±0.18
1.406 ±0.22

0.459 ± 0.12
0.654 ± 0.08

2.826
2.773

Mean

I
N

0.847
0.687

0.603
0.708

0.159
0.495

1.573
1.901

*Data shown represent the mean of four independent experiments ± SEM.
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Fraction: -WC__ EC,
passage: p5 p23
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.QE
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Figure 2. Detection of P39, OspB, and OspA in infectious CN40 cell fractions at
p5 and p23 by westernblot. Eight microliters o f whole cell sonicate (WC),
protoplasmic cylinder (PC), outer envelope (OE), cytosolic (CY), or inner membrane
(IM) fraction were analyzed.
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Fraction: _QE
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Figure 3. Detection of P39, OspB, and OspA in low and high passage B31 cell
fractions by western blot. A total of eight microliters o f outer envelope (OE),
cytosolic (CY), or inner membrane (IM) fractions were analyzed.
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Fraction: _CY_
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Figure 4. Detection of P39, OspB, and OspA in low and high passage WCH1 cell
fractions by western blot. Eight microliters of cytosolic (CY), inner membrane
(IM), and outer envelope (OE) fractions were analyzed. Flagellin control is marked
(>) in IM fraction.
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Figure 5. Detection of Fla, P39, OspB, and OspA in low and high passage JD1
cell fractions by western blot. Eight microliters of outer envelope (OE), cytosolic
(CY), or inner membrane (IM) fractions were analyzed.
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Table 3. OspB levels in Borrelia burgdorferi cell fractions measured by
western blot densitometry.*

Isolate

Infectivity

OE

IM

CY

Cumulative

CN40 (p5)
CN40 (p23)

I
I

0.863 ± 0.20
0.988 ± 0.30

0.181 ±0.11
0.098 + 0.15

0
0

1.044
1.086

B31
B31

I
N

0.426 ±0.20
1.16 ±0.22

0.850 ±0.20
1.99 ±0.31

0.286 ±0.14
1.8 ±0.45

1.562
4.950

WCH1
WCH1

I
N

1.793 ±0.32
1.246 ±0.27

1.796 ±0.42
1.834 ±0.48

0.298 ±0.10
0.248 ±0.04

3.887
3.328

JD1
JD1

I
N

0.954 ±0.34
0.481 ± 0.20

1.350 ±0.41
1.520 ±0.49

0.426 ±0.17
0.323 ±0.15

3.684
2.324

Mean
Mean

I
N

1.009
0.968

1.044
1.360

0.252
0.592

2.544
2.922

*Data shown represent the mean of four independent experiments ± SEM.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

46

Table 4. OspA levels in Borrelia burgdorferi cell fractions measured by western
blot densitometry.*

Isolate

Infectivity

OE

IM

CY

Cumulative

CN40 (p5)
CN40 (p23)

I
I

0.922 ±0.20
0.994 ±0.20

0.732 ±0.30
0.435 ±0.40

0
0

1.654
1.429

B31
B31

I
N

0.555 ±0.20
1.05 ± 0.70

1.138 ±0.22
1.93 ±0.40

0.413 ±0.21
1.25 ±0.32

2.106
4.230

WCH1
WCH1

I
N

1.781 ±0.18
1.825 ±0.12

2.079 ±0.17
2.008 ± 0.25

0.742 ±0.18
0.675 ±0.18

4.602
4.508

JD1
JD1

I
N

1.238 ±0.50
1.150 ±0.40

2.590 ±0.61
2.240 ±0.43

1.120 ±0.37
1.090 ±0.38

4.948
4.480

Mean
Mean

I
N

1.124
1.254

1.634
1.653

0.568
0.753

3.327
3.661

*Data shown represent the mean of four independent experiments.
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Table 5. Flagellin levels in Borrelia burgdorferi cell fractions measured by
westernblot densitometry.*

Isolate

Infectivity

OE

IM

CY

Cumulative

CN40 (p5)
CN40 (p23)

I
I

0
0

ndb
nd

nd
nd

nd
nd

B31
B31

I
N

0
0

nd
nd

nd
nd

nd
nd

WCH1
WCH1

I
N

0
0

0.426
0.611

0.030
0.050

0.456
0.661

JD1
JD1

I
N

0
0

0.734°
0.909d

0.155
0.045

0.889
0.954

Mean
Mean

I
N

0
0

0.58
0.76

0.092
0.047

0.672
0.807

“Data shown represent the mean of four independent experiments. SEM <
0.05 unless otherwise indicated.
bnd = not determined.
CSEM = 0.2
dSEM = 0.1
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In infectious B31 cell fractions, the P39 was located in the membrane fractions only.
However, noninfectious fractions had considerably more P39 and the majority was in
the cytosolic fraction. For the other uncloned isolates WCH1 and JD1, P39 was
detected in all fractions (Fig. 4 and 5). However, decrease in P39 was detected in the
noninfectious outer envelope fraction of WCH1 and JD1 (Table 2). This decrease
corresponds with a slight increase in noninfectious inner membrane fractions, and
cytosolic fraction for both isolates.
b. OspB levels
No significant interaction exists between infectivity and OspB localization in
any cell fraction: outer envelope (P = 0.65) inner membrane (P = 0.20), cytosol (P =
0.65). For the infectious CN40, OspB levels were observed in both the outer envelope
and inner membrane fractions but were not seen in the cytosolic fractions (Table 3, Fig.
2). Notably, the OspB levels for CN40 did not change from low to high passage. In
contrast, OspB (Table 3, Fig.3) was detected in all fractions o f B 31, but noninfectious
cell fractions contained twice the amount of OspB. OspB was also detected in all
fractions o f WCH1 and JD1 (Table 3). The amount of OspB in the outer envelope
fraction decreased in both noninfectious WCH1 and JD1, but inner membrane and
cytosolic levels remained the same.
c. OspA levels
No significant interaction exists between infectivity and OspA localization in any cell
fraction: outer envelope (P = 0.15), inner membrane (P = 0.27), cytosol (P = 0.19).
For CN40, OspA was detected in both the outer envelope and inner membrane
fractions but were not seen in the cytosolic fractions (Fig. 2, Table 4). CN40 OspA
levels did not change with in vitro culture, this is consistent with CN40 P39 and OspB
levels. In contrast, OspA was detected in all fractions of B31, but noninfectious cell
fractions contained twice the amount of OspA (Fig.3, Table 4). OspA was also
detected in all cell fractions of WCH1 and JD1 (Table 4). OspA was equally
distributed between the membrane fractions of WCH1, and did not change with
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infectivity. For JD1, the majority of OspA was located in the inner membrane fraction,
and this did not change with infectivity. For all isolates there was no significant
correlation between OspA localization and infectivity.

d. Flagellin levels
Flagellin levels were monitored simply as a quality control measure for the cell
fractionation procedure. No flagellin was detected in any outer envelope fraction,
indicating proper fractionation o f the isolates (Table 5). Flagellin was detected in the
inner membrane fraction and trace amounts in the cytosol. Noninfectious and
infectious isolates had similar flagellin levels in the inner membrane fraction.

2. Quality control measures for fractionation technique and densitometry
analysis
a. Interassay variation of cell fractionation
The reproducibility o f the fractionation procedure was monitored by protein
assay. The protein distribution within spirochete cell fractions was as follows: 90-93%
in the outer envelope, 4-8% in the inner membrane, and 0.6-1.8% in the cytosolic
fraction. The average amount o f protein from 1 xlO6 infectious spirochetes was 2.0 mg
(93% o f total) in the outer envelope, 0.1 mg (4.6% o f total) in the inner membrane, and
0.04 mg (1.8% of total) in the cytosolic fraction. When the protein concentrations of
the cell fractions were added together in all cases the total was equal to (100%) or
slightly higher than (101-107%) the protein concentration for the whole cell sonicate
preparation. For noninfectious organisms, there was nearly twice as much protein
from the same number o f spirochetes: 4.0 mg in the outer envelope, 0.2 mg in the
inner membrane and 0.07 mg in the cytosolic fraction. The protein concentration of
cell fractions generated from duplicate samples of CN40 (two populations o f CN40
subjected to cell fractionation on different occasions) were analyzed by students T test.
No significant differences exist between protein concentrations of cell fractions from
duplicate samples (P =0 .3736).
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b. Localization of cell fraction markers
The flagellin protein is the major component o f the spirochete flagella.
Physiologically it is anchored to the inner membrane. When the cell is fractioned, the
flagellin should partition with the inner membrane fraction. Any detection o f flagellin
in the outer envelope fraction would be evidence of improper separation of the
fractions. There was no control for outer membrane contamination of the inner
membrane or cytosolic fractions as no outer envelope specific marker had been
identified for B.burgdorferi. For all isolates analyzed, no flagellin was detected in the
outer envelope fraction indicating proper fractionation of the cell (Table 5). Flagellin
was detected primarily in the inner membrane fraction, and trace amounts (0-2%) were
detected in the cytoplasmic fraction of WCH1 and JD1.

c. Western blot/densitometry assessment
To ensure proper detection o f bands by the densitometer, the densitometer sensitivity
was assessed. Duplicate serial dilutions o f whole cell B.burgdorferi antigen (Oug30ug) were subjected to SDS-PAGE and western blot (purified P39, OspB, or OspA
were not used for assessment o f the densitometer since cell fractions, not purified
proteins, are the subject o f this study). The blot was treated with monoclonal
antibodies specific for P39, OspA, and OspB and developed as described above. A
linear relationship was demonstrated between densitometer absorbance readings and
serial dilutions o f whole cell B.burgdorferi antigen less than 30 ug (P39 Y = 0.04X +
0.628; OspB y = 0.037X + 0.167; OspA Y = 0.0368X + 0.3568) (Appendix 3).
Therefore, the densitometer was able to quantitate P39, OspA, and OspB in antigen
samples less than 30ug. The protein concentration in 8ul of each cell fraction (2.8 x 10s
spirochetes, the amount used in the SDS-PAGE in this study) is less than 15 ug. All
fractions from one isolate (both low and high passage) were analyzed on the same blot,
thereby minimizing differences in development. A minimum of three experiments
were performed with each isolate, and densitometry readings were analyzed by linear
regression analysis to determine the statistical significance.
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3. Silver stain analysis of cell fractions
Cell fractions o f the infectious and noninfectious spirochetes were also
analyzed by SDS-PAGE and silver stain to detect any other changes in protein
expression which might correlate with loss of infectivity. All isolates (infectious and
noninfectious) had bands migrating at 14,20,22 (corresponding to OspC), 29,32
(corresponding to OspA), 34 (corresponding to- OspB), and a large band at 50-66 kD in
the whole cell sonicate (Figs.6-9).

a. Outer envelope fraction
For all isolates, the majority of detectable proteins were in the outer envelope
fraction. Most bands detected in the whole cell sonicate were also detected in the
outer envelope. For the infectious isolate CN40, all corresponding bands in low and
high passage fractions appeared to stain with equal intensity (Fig. 6). For isolate
B31, infectious and noninfectious outer envelope fractions displayed different
staining intensities for many bands; most notably bands o f 24,22 and 20 kD were all
detectable in the infectious outer envelope fraction yet absent from the noninfectious
fraction (Fig. 7). WCH1 also exhibited several differences between infectious and
noninfectious outer envelope fractions (Fig. 8). Infectious outer envelope had
distinct bands migrating at 36 and 39 kD. In the noninfectious fraction the 36 kD
band was greatly diminished and the 39 kD band was completely absent. All other
corresponding bands in WCH1 outer envelope fractions appeared to have equal
intensity. JD1 also exhibited changes in band intensities between infectious and
noninfectious outer envelope fractions (Fig. 9). The noninfectious outer envelope
fraction contained darker bands migrating at 47,45,34, 32, and 14 kD, but a lighter
band at 29 kD as compared to the corresponding infectious fraction.

b. Innermembrane fraction
For all isolates very few bands were detected in the inner membrane fraction.
All isolates (except JD1) had a 66 kD band. CN40 also had a band at 20 kD in the high
passage fraction. For B31, faint bands at 41, 33, and 21 kD could be seen in the
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Figure 6. Silver stain analysis of infectious isolate CN40 cell fractions.
Eight microliters of the cell fractions are represented in each lane. Whole
cell sonicate (WC), outer envelope (OE), inner membrane (IM) and cytosolic
(CY) fractions are shown. Molecular weight markers are indicated to the left
o f the gel.
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Figure 7. Silver stain analysis of B31 cell fractions. Eight microliters of
cell fractions were electrophoresed on a 12.5% gel and silver stained to detect
proteins. Whole cell sonicate (WC), outer envelope (OE), inner membrane
(IM) and cytosolic (CY) fractions from infectious (I) and noninfectious (N)
B 31 are shown. Molecular weight markers are indicated to the left o f the gel.
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Figure 8. Silver stain analysis of WCH1 cell fractions. Eight microliters of
cell fractions were electrophoresed on a 12.5% gel and silver stained to detect
proteins. Whole cell sonicate (WC), outer envelope (OE), inner membrane
(IM) and cytosolic (CY) fractions from infectious (I) and noninfectious (N)
WCH1 are shown. Molecular weight markers are indicated to the left of the
gel.
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Figure 9. Silver stain analysis of JD1 cell fractions. Eight microliters of
cell fractions were electrophoresed on a 12.5% gel and silver stained to detect
proteins. Whole cell sonicate (WC), outer envelope (OE), inner membrane
(IM) and cytosolic (CY) fractions of infectious (I) and noninfectious (N) JD1
are shown. Molecular weight markers are indicated to the left of the gel.
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noninfectious inner membrane fraction, but were not seen in the infectious inner
membrane fraction. For WCH1, bands migrating at 29,41, and 60 kD were detected
in both inner membrane fractions but appeared to be darker in the noninfectious
fraction. Additional bands at 52,54, and 60 kD were also evident in the noninfectious
inner membrane fraction. For JD1 both inner membrane fractions had bands of equal
intensity migrating at 29,31, and 41 kD.

c. Cytosolic fraction
All isolates displayed a single large band at 66 kD for both cytosolic fractions.
For CN40 this was the only band detected. A distinct band in the cytosolic fraction of
infectious B 31 migrated at 66 kD, while the noninfectious cytosolic fraction contained
several additional faint bands at 60,40,34,33,22, and 18 kD. A single band of 66 kD
was detected in both cytosolic fractions of WCH1, although it appeared to be more
intense in the noninfectious passage. Additionally, both cytosolic fractions from JD1
contained a single band migrating at 66 kD, but the band in the noninfectious fraction
was considerably darker. Proteins are present in the inner membrane and cytosolic
fractions as evidenced by BCA protein assay; however, not all proteins are detected by
silver staining, and the intensity of staining depends upon the individual characteristics
of each protein.
These data demonstrate several differences in protein expression between
infectious organisms and noninfectious organisms. CN40 alone remains unchanged in
low and high passage. B31 had two bands in the outer envelope fractions with
different intensities (29 kD and 20 kD), and the noninfectious inner membrane and
cytosolic fractions both contained bands which were not found in the corresponding
infectious fractions. WCH1 noninfectious outer envelope fraction lacked two bands
(36 kD and 39 kD) found in infectious fraction, and overall noninfectious fraction
bands were darker in both inner membrane and cytosolic fractions. JD1 had disparity
in band intensities between infectious and noninfectious cell fractions, but the loss or
gain o f bands was not noted. The fact that B31, WCH1, and JD1 are uncloned
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populations o f spirochetes may account for the differences seen between low and high
passage organisms.

C. Surface expression of P39, OspB, and OspA as detected by flow cytometry
The uniformity o f P39, OspB, or OspA surface expression in a population of
spirochetes was assessed by flow cytometry. Distinct peaks show uniformity of
expression in a population. Flat or broad peaks are a sign of variability in surface
expression among the population of spirochetes.

1. Differences in levels of P39 expression in clones derived from parental isolate
WCH1
Clones o f isolate WCH1 were generated for this study in order to compare P39
surface expression o f clones to the original uncloned population o f spirochetes.
Parental, uncloned WCH1 and WCH1 clones were first analyzed by ELISA for P39
expression. A single clone, Clone 1, showed marked differences in P39 reactivity as
compared to uncloned WCH1. Clone 1 had higher P39 reactivity in whole cell antigen
preparations than uncloned WCH1 (O.D. values at 260 nm were 0.62 versus 0.38
respectively). All other clones had P39 reactivity similar to uncloned WCH1. Due to
the differences in P39 reactivity, Clone 1 was selected for further study by flow
cytometry.

2. P39 surface expression
In order to determine the variability o f P39 surface expression in cloned and
uncloned isolates, low and high passage whole cell B31, WCH1, JD1, WCH1 clone 1,
and high passage CN40 were analyzed by flow cytometry. The infectious, cloned
isolate CN40 had a single, very low intensity peak for P39 indicating the cloned
spirochetes’ uniform reactivity to Mab D1C9 (mean fluorescence = 72.9, Table 6,
Fig. 10). A single peak was also observed in both low and high passage WCH1 clone 1,
and had a mean fluorescence o f 111.5 for p7 and a mean of 104.0 for p 17. The P39
reactivity was not uniform in the uncloned isolates B31, WCH1, and JD1. Infectious
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Table 6. Surface expression of P39, OspB, and OspA as detected by flow
cytometry.
Isolate

Infectivity

P39

OspB

OspA

CN40 p22

I

72.9 ±31.4

165.6 ±35.7

120.7 ±45.3

clone I p7
clone I pl7

ndb
nd

111.5 ±29.1 100.7 ±30.4
104.0 ±35.4 136.0 ±36.1

59.2 ±26.8
50.4 ± 23.8

B31
B31

I
N

nd
140.8 ±44.0
84.7 ±34.1 103.4 ±26.5

nd
41.6 ± 22.8

WCH1
WCH1

I
N

130.8 ±51.3
107.4 ±38.3

135.4 ±33.4
143.4 ±32.7

54.7 ± 25.8
73.2 ±30.0

JD1
JD1

I
N

136.6 ± 51.3 126.9 ±33.5
88.3 ±33.8 116.2 ±32.0

51.2 ±24.3
66.8 ± 26.2

aMean fluorescence ± standard error are shown.
b nd= not determined.
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Figure 10. P39 surface expression as detected by flow cytometry. Infectious (I) and
noninfectious (N) spirochetes were incubated with monoclonal D1C9, followed by a
fluoroscein labeled secondary antibody, and assessed by flow cytometry. Panel A isolate
CN40, panel B WCH1 clone 1 p7 and p 17 (infectivity unknown), panel C isolate B31,
panel D isolate WCH1, and panel E isolate JD1.
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Figure 11. OspB surface expression as detected by flow cytometry. Infectious (I) and
noninfectious (N) spirochetes were incubated with monoclonal H6831, followed by a
fluoroscein labeled secondary antibody and assessed by flow cytometry. Panel A isolate
CN40, panel B WCH1 clone 1 p7 and p l7 (infectivity unknown), panel C isolate WCH1
and panel Disolate JD 1.
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Figure 12. OspA surface expression as detected by flow cytometry. Infectious (I) and
noninfectious (N) spirochetes were incubated with monoclonal antibody H5332,
followed by a fluoroscein labeled secondary antibody and assessed by flow cytometry.
Panel A isolate CN40, panel B WCH1 clone 1 p7 and p 17 (infectivity unknown), panel
C isolate B 31, panel D isolate WCH1, and panel E isolate JD 1.
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B31, JD1, and WCH1 all displayed skewed peaks. In addition, all uncloned isolates
exhibited higher P39 surface expression in the infectious population than the respective
noninfectious population. The nonifectious samples’ peaks remained skewed but there
was a noticeable overall decrease in P39 reactivity. These data demonstrate the shift in
outer surface P39 expression in uncloned organisms upon in vitro cultivation. This
change may be due to a selection during in vitro culture of a particular subpopulation of
spirochetes, or a change in the expression of the protein within the whole population of
spirochetes.

3. OspB surface expression
All isolates had very distinct peaks for OspB (Fig. 11). Clone 1 increased from a
mean fluorescence of 100 to a mean o f 136 from p7 to p i7, but all other isolates
remained relatively unchanged (Table 6). Overall OspB expression appeared
uniform throughout cloned and uncloned populations, and did not change in intensity
from low to high passage.

4. OspA surface expression
CN40 displayed two distinct peaks for OspA reactivity demonstrating two
subpopulations varying in OspA expression (Fig. 12). Either there are two
subpopulations within this cloned population of spirochetes, or the spirochetes are
differentially regulating the OspA expression. All other isolates, cloned and
uncloned, had single distinct peaks for OspA expression indicating uniform surface
expression o f this molecule.

D. Characterization of P39
1. Solubility of P39 as determined by detergent extraction
In the cell fractionation experiment, P39 was detected in membrane fractions
as well as cytosolic fractions. Therefore the question of the solubility of P39 was
raised. Is P39 localizing to the cytosolic fractions because of a change in the solubility
of the molecule? B31 was the isolate with the most dramatic shift in P39 localization
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in infections and noninfectious populations (from membrane to cytosol, Table 2) and
was therefore selected for further study. For comparison CN40 was selected because it
retains infectivity and does not exhibit a change in P39 localization. Based on these
criteria, the localization of P39 within the isolates B31 and CN40 was determined
utilizing detergent solublization of whole cell sonicates, outer envelope, inner
membrane, and cytosolic cell fractions.
P39 consistently localized to the Triton X I 14 soluble fraction indicating the
hydrophobic nature of the molecule. For CN40, P39 was detected in the Triton X I14
soluble phase o f the outer envelope fraction (Fig. 13). For B31, P39 was detected in
the Triton X I 14 soluble phase of whole cell sonicate and all three subcellular fractions
(Fig. 14). This pattern of P39 localization in CN40 and B31 was also seen in the
western blot analysis (Fig. 2 and 3). The consistent partitioning to the Triton X I14
fraction indicates P39 is hydrophobic in nature and does not exhibit any change in
solubility in infectious or noninfectious spirochetes or in different cell fractions.
Therefore, the reason for the change of P39 localization in infectious and noninfectious
B31 is not due to a change in the solubility o f the P39 molecule.

2. Proteins associated with P39
If the change in P39 localization in infectious and noninfectious isolates is not
due to a change in the solubility of the P39 molecule, perhaps it is due to the molecules
with which P39 associates. This was investigated by immunoprecipitating P39 (using
Mab D1C9) from whole cell sonicates of CN40, B31, WCH1, and JDl and identifying
any coprecipitating molecules. Using Pansorbin for the affinity purification of these
complexes, a band corresponding to P39 was detected in all isolates. Figure 15 shows
the results o f immunoprecipitation from whole cell sonicates. Controls include the
following: whole cell antigen immunoprecipitated in the absence of D1C9 (Ag); D1C9
immunoprecipitated in the absence of antigen (Mab); and Pansorbin with no antigen or
antibody (Pan). Bands seen in the control lanes (designated nonspecific bands) include
a 65, 54,52,41,36,26, and 16 kD bands. These bands appeared in the
immunoprecipitations from the isolates and will not be discussed further. P39 was
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PCp5 0Ep5 PCp23 OEp23
dt aq dt aq dt aq dt aq

Fig. 13 W estern blot detection o f P39 in detergent extracted cell
fractions o f infectious CN40. Triton X I 14 was used to separate
hydrophobic and hydrophilic molecules in cell fractions o f isolate
CN40. Detergent soluble (dt) and aqueous (aq) phases of CN40
protoplasmic cylandar (PC), and outer envelope (OE) fractions from
p5 and p23are shown.
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WC
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dt aq
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dt aq

OE
dt aq

Figure 14. Western blot detection of P39 in detergent extracted cell
fractions of noninfectious B31. Triton X I14 was used to separate
hydrophobic and hydrophilic molecules in cell fractions o f isolate B31.
Detergent soluble (dt) and aqueous (aq) phases of high passage B31 whole cell
(WC), cytosolic (CY), inner membrane (IM), and outer envelope (OE) fractions
are shown.
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Control
Ag

Mab Pan

CN40

B31

WCH1 JD1

Figure 15. Immunoprecipitation of P39 from high passage whole cell sonicate
of infectious isolate CN40 and noninfectious isolates B31, WCH1, and JD1.
Controls include B31 sonicate (Ag), Monoclonal D1C9 (Mab), and Pansorbin cells
(Pan). P39 was detected in all isolates (P39). Coprecipitating molecules found only
in B31, W CH1 and JD 1 are indicated with an arrow (>). Molecular weight markers,
in kilodaltons, are indicated at left.
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detected in all isolates. Bands common to all four isolates include 50,39, 15, and 13
kD. Six additional bands found in all three noninfectious isolates, but not in the
infectious isolate CN40 include 60,46,38,32,22, and 21 kD. In addition, there were a
29 kD and 9 kD band detected only in B31.

E. Attempts to genetically mutate the cloned P39 gene
1. P39-LacZ fusion
The first attempt to knock out P39 in B.burgdorferi was based on creating a
P39-LacZ fusion gene. However, no successful ligations of P39 and LacZ DNA were
detected in E.coli. Twenty five different reactions were attempted, utilizing enzymes
and buffers from different manufacturers in an attempt to optimize the reaction. No
successful P39-LacZ fusion gene was obtained. Therefore, instead of mutating the
gene by insertion o f a selectable marker, the P39 gene was mutated by deletion.

2. P39 deletion-mutant
Deletion o f a 300 bp fragment from the cloned P39 gene and religation to yield
a product which was out o f frame and no longer expressed P39 was successful on the
first attempt. The P39 deletion mutant construct did not express a protein recognized
by the Mab D1C9 as demonstrated by ELISA. The absorbance for the wild type P39
(E.coli expressing cloned P39 gene) at 260 nm was 2.30 O.D., whereas the absorbance
for the P39 deletion mutant (E.coli expressing mutant construct) was 1.40 O.D, and the
negative control (E.coli with control vector) was 1.47 O.D.. In addition to providing a
deletion-mutant construct for use in transforming B.burgdorferi, this experiment
confirmed that the epitope for D1C9 is not contained within the first 100 amino acids
(300 nucleotides) o f P39.

3. Screening for transformed B.burgdorferi
CN40 was the isolate selected for use in this experiment because it does not
lose infectivity during in vitro culture. CN40 was electroporated with the linearized
P39 deletion mutant gene. Electroporated spirochetes were assayed by ELISA for

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

68

expression of flagellin and P39. Out o f 2430 organisms 18 were concurrently positive
for flagellin expression and low for P39 expression (as compared to untransformed
organisms.) The qualification for a spirochete being P39 “low” was 0.1 O.D. units
below the untransformed control spirochetes. This generous cut off point will
invariably include P39 expressing spirochetes since this value is within the standard
error o f the mean (0.2). The purpose was to ensure no transformants were excluded,
even if this meant including several nontransformed spirochetes. The 18 putative
transformants were grown in culture for two weeks to increase the number of
organisms. The spirochetes were subsequently-harvested from culture and assayed by
western blot to assess the P39 expression. However, all spirochetes expressed P39 as
detected by western blot. Therefore, no B.burgdorferi P39 deletion mutants were
obtained, and the question o f P39’s role in infectivity o f B.burgdorferi, and its role in
the pathology of Lyme disease could not be directly addressed.
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IV. CONCLUSIONS

The purpose of this study was to biochemically characterize the P39 molecule
and determine if a correlation exists between P39 expression and infectivity of Borrelia
burgdorferi. The first aim was to determine where P39 is located within the spirochete,
and determine if localization o f P39 correlates with infectivity. This comparative
analysis necessitated the establishment of infectious and noninfectious isolates of
B.burgdorferi.
Four different isolates were used in this study, and three separate methods were
used for verifying isolate infectivity: culture of mouse tissue, xenodiagnosis using
ticks, and PCR o f mouse tissue. The first isolate CN40, which is the only isolate
known to retain infectivity during prolonged in vitro culture, was shown to be
infectious at passage 9 and passage 22 by tissue culture. The remaining isolates B31,
WCH1, and JD1 (all uncloned organisms) were infectious at or below passage 6. Each
isolate was recovered from the tissues of inoculated mice demonstrating persistence of
spirochetes in tissues of the host. Transmission of spirochetes from infected mice to
ticks, an important part of maintaining the B.burgdorferi population in the wild, was
also demonstrated for isolates WCH1 and JD1. Other investigators report the
transmission rate of WCH1 or JD1 from experimentally infected mice to feeding ticks
is 1-10% (personal communication). Thus the transmission rate in this experiment,
4.3% for WCH1 and 15% for JD1, is consistent with similar findings made elsewhere.
When B31, WCH1, and JD1 were passed 15 or more times they were not
recovered from the tissues of inoculated mice and were not transmitted to ticks. To
ensure that the high passage isolates were not simply more difficult to isolate from
tissue, PCR was performed on mouse tissues. No B.burgdorferi DNA was detected at
a sensitivity o f 10 pg of spirochete DNA/500 pg mouse DNA, confirming the lack of
infectivity of these high passage isolates. These infectious and noninfectious
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spirochetes were next analyzed for P39 localization to determine if a correlation exists
between P39 localization and infectivity.
As shown in the western blot/densitometry analysis o f cell fractions, there was
a statistically significant interaction between P39 localization (outer envelope fraction
only) and the infectivity o f B.burgdorferi. High levels of P39 in the outer envelope
correlated with infectivity of the spirochete. A decrease in P39 levels in the outer
envelope correlated with a loss o f infectivity. No significant interaction with
infectivity was detected for P3 9 in the remaining cell fractions, nor for OspB or OspA
in any cell fraction. This supports the hypothesis that P39 localization is related to the
infectivity of B.burgdorferi.
Interestingly, the cloned infectious isolate CN40 localized P39 exclusively to the outer
envelope. Continuous culture of CN40 did not affect the localization of P39 nor the
quantity produced. In contrast, P39 was localized to all three cell fractions of uncloned
isolates WCH1, JD1, and B31 and continuous culture did affect the localization of P39
in these three isolates. Noninfectious WCH1 and JD1 had far less P39 in the outer
envelope and more P39 in the inner membrane and cytosol, whereas noninfectious B31
had a dramatic increase of P39 in the cytosol. This shift in P39 localization was also
demonstrated in the flow cytometry analysis; noninfectious B31, WCH1, and JD1 had
uniformly decreased surface expression o f P39 as compared to the corresponding
infectious isolates. The changes noted in P39 localization in noninfectious B31,
WCH1, and JD1 may have been due to clonal expansion o f a particular subgroup of
spirochetes in the uncloned population, or a widespread phenotypic change by the
whole population o f spirochetes. The cell fractionation/western blot procedure does
not allow for differentiation between the two possibilities.
Other changes were detected in these three uncloned isolates as shown by silver
staining. In comparison of infectious and noninfectious outer envelope, each uncloned
isolate had at least two bands which differed in intensity: B31 had bands at 24,22 and
20 kD; WCH1 had bands at 39 and 36 kD; JD1 had bands at 47,45,34,32,29, and 14
kD. The cloned, infectious isolate CN40 exhibited no detectable changes in banding
patterns in low and high passage cell fractions. For all isolates the majority o f proteins
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detected by silver stain were located in the outer envelope fraction. Few proteins were
detected in the inner membrane and cytosolic fractions even though proteins were
present in those fractions as evidenced by western blot.
Previous studies have compared infectious and noninfectious isolates by SDSPAGE silver stain and western blot (65,68,73,75,103). All o f these studies have
used whole cell organisms and have not analyzed possible differences in protein
localization within the spirochetal cell. Subtle changes in protein localization, such as
those described in this study, would be easily overlooked by simple total protein
analysis. Some previously documented changes of B31 as a result of in vitro culture
are as follows; decrease in 24 and 20 kD molecules (also documented in the present
study) and loss o f 35 and 28 kD molecules (75), and in another study using B31
documented the loss o f 28,26, 18 and 16 kD proteins (117).
Other investigators have selectively studied the outer envelope o f the B.
burgdorferi in hopes of identifying virulence factors, and have separated the
spirochetal cell using isopicnic centrifugation after disruption of the cell in a French
pressure cell (133). However this allows mixing of the different cell fractions prior to
separation of the fractions. This process may artificially allow proteins to separate into
fractions in which they were not originally located. In order to avoid this dilemma in
the present study the outer envelope was first removed from the protoplasmic cylinder
using a mild detergent solution. This outer envelope fraction was then separated from
the protoplasmic cylinder by centrifugation. The protoplasmic cylinder was then
sonicated to break apart the cell, and inner membrane and cytosolic constituents were
separated by centrifugation. This modified procedure reduces the possibility of
artifactual redistribution o f antigens among the cell fractions.
Perhaps what P39 is “doing” in the outer envelope is important. What is P39
bound to or complexed with in the outer envelope? As shown by immunoprecipitation,
molecules associating with P39 in all four isolates include 50, 39, 15 and 13 kD. All
noninfectious isolates had the following additional molecules: 60,46,38,22, and 21
kD. In addition, isolate B31 had bands at 29 and 9 kD. Therefore there is a distinct
difference in the molecules associating with P39 in infectious and noninfectious
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isolates. One must note that P39’s association with other molecules may result in the
masking o f the P39 epitope recognized by D1C9, therefore it is possible not all
molecules interacting with P39 will be identified.
It also should be noted that the amount of a molecule contained within the outer
envelope fraction is not necessarily indicative o f how much o f that molecule is actually
surface exposed. For example, in the western blot/densitometry analysis infectious
B31 had the least amount o f P39 in the outer envelope o f all the isolates, yet it had the
highest flow cytometry reading for surface exposed P39. From these data it appears
that all or most o f the P39 in the outer envelope of infectious B31 is surface exposed.
In contrast, the infectious isolate CN40 flow cytometry analysis revealed that very little
P39 is actually surface exposed. Indeed, the surface exposed P39 in high passage
infectious CN40 was less than any other isolate either infectious or noninfectious.
Either the P39 in CN40 outer envelope is located on the inner leaflet of the outer
envelope thereby limiting surface exposure, or the P39 epitope is masked by another
molecule at the cell surface.
Flow cytometry analysis also revealed that uncloned infectious isolates did
have more P39 surface exposed than the corresponding noninfectious isolates as was
seen in the western blot/densitometry analysis. Furthermore, infectious B 31, JD1, and
WCH1 had variable surface expression of P39. All exhibited broad, skewed peaks
illustrating a lack of uniformity in P39 surface expression within the population of
spirochetes. These same isolates did have more uniform reactivity in the noninfectious
populations. Notably, all three uncloned populations exhibited the same shift from
high P39 surface expression to low P39 surface expression. This may be due to a
selection o f the lower expressing population over a period o f time, or it may be due to a
change in the expression of the P39 protein by all spirochetes within the population.
Another point to note is that surface protein expression can vary even within a
cloned population as demonstrated by CN40 expression o f OspA. Two distinct
populations were detected by flow cytometry. In past research OspA expression has
been demonstrated as being differentially regulated by temperature, but all cultures in
this study were maintained at the same temperature. Therefore another regulatory
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mechanism must be involved. Another point is that uncloned isolates such as B31,
WCH1 and JD1 can vary in surface expression o f one molecule (P39) and yet have
uniform expression in other surface exposed molecules (OspB and OspA). This also
occurs for cloned isolate CN40, OspA expression is varied and yet P39 and OspB
expression is uniform throughout the population. This varying of surface exposed
molecules may be advantageous to the spirochete in evasion of immune responses. A
recent study documenting Osp localization to both outer envelope and inner membrane
fractions concluded that B.burgdorferi may uncouple lipoprotein expression from
surface localization as part o f their parasitic strategy for evasion of humoral immune
response (102). This theory is supported in part by the findings in the present study;
Osps located in both membrane fractions o f the spirochete, and a shift of location of
surface exposed molecules by cloned and uncloned organisms. No immune pressure
was placed on these organisms since they were grown in vitro, therefore the primary
purpose for this shift may be entirely unrelated to immune evasion.
In the present study P39 was detected primarily in membrane fractions,
therefore it would seem logical that P39 be hydrophobic. Since P39 was also detected
in the cytosol of the uncloned isolates (most prominently in noninfectious B31), it
raised the possibility that P39 may be modified in a way which would affect the
solubility o f the molecule. The solubility o f P39 has not previously been investigated.
Other researchers utilizing Triton X I14 have reported a detergent soluble protein of 39
kD obtained from isolate B31 (132), but did not confirm the identification of the
molecule with a monoclonal antibody. The present study demonstrated, using western
blot as confirmation, that P39 consistently localized to the detergent soluble fraction of
B31 in all cell fractions tested. This was also the case for isolate CN40. This indicates
P39 is hydrophobic in nature and does not exhibit any change in solubility from low to
high passage or in different cell fractions. Therefore, the reason for the change of P39
localization in infectious and noninfectious B31 is not due to a change in the solubility
o f the P39 molecule. P39 may be associating with additional molecules in B31, such
as the 29 and 9 kD molecules seen in the immunoprecipitation experiment, and this
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may be responsible for the dramatic increase of P39 in the cytosol o f noninfectious
B31.
There is a statistically significant relationship between P39 levels in the outer
envelope o f a spirochete and the infectivity o f that spirochete. However, statistical
significance does not necessarily translate into a cause and effect relationship in regards
to infectivity. The only way to prove that P39 expression is required for the infectivity
o f B.burgdorferi is to create a P39-less mutant and assess the infectivity o f that mutant.
Even if a P39-less mutant remained infectious, it could be used to assess the role of
P39 in the pathology of Lyme disease. For this study an attempt was made to create a
P39-less mutant B.burgdorferi. The use of electroporation and homologous
recombination has previously been demonstrated as an effective route o f genetic
manipulation in B.burgdorferi (136). The first attempt consisted o f creating a P39LacZ fusion for use in electroporation. Despite much effort, no functional construct
was obtained. The second attempt utilized a P39 deletion mutant construct; instead of
inserting DNA as a mode o f gene disruption, DNA was deleted. Screening by loss of
P39 signal was not ideal but still an option. The transformation efficiency in
B.burgdorferi using linear DNA is 103/1 g of DNA, therefore at least 2,000 of the
10,000 electroporated organisms were expected to be successfully transformed under
the conditions used. The putative transformants were screened both by ELISA and by
western blot. No spirochetes could be detected which lacked expression of P39. It is
possible that P39 is an essential protein for routine function of the bacterial cell and
therefore any transformants carried a lethal mutation.
The changes in P39 localization of infectious and noninfectious organisms seen
in this study may be indicative o f a novel protein localization regulatory mechanism,
operating in vivo. This regulation differs from the temperature regulation of OspA, and
OspC; changes in temperature have no affect on the expression of P39 (105). The
change in P39 localization seen in this study also differs from the antigenic variation
seen in Borrelia hermsii, the causative agent of relapsing fever, which alters the
expression o f surface exposed lipoproteins by actual rearrangement o f the DNA. This
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novel change in P39 localization may explain B.burgdotferVs successful immune
evasion in vivo. Clinical evidence shows the strong anti-P39 humoral response seen in
an infected host fails to clear the B.burgdorferi infection. Yet P39 specific antibodies
have been shown to be highly bactericidal in vitro (83). Perhaps P39 surface
expression is required only during the initial establishment o f infection, and the surface
exposure o f P39 facilitates development of the early P39 specific humoral response. It
is possible that after the initial infection all or some o f the spirochetes decrease the
amount o f P39 that is surface exposed thereby evading the anti-P39 antibodies. This
type o f regulation o f surface exposed molecules may be the key to infectivity and to
how B.burgdorferi successfully evade the hosts immune response.
In summary, this study provides groundwork information which is necessary
for a more complete understanding of P39 and B.burgdorferi infectivity. The results o f
this study show that P39 is localized primarily to the outer envelope and inner
membrane o f B.burgdorferi. Infectious isolates have a higher level of P39 in the outer
envelope as compared to noninfectious isolates. P39 was shown to be hydrophobic in
nature and this remained unchanged in all cell fractions o f infectious and noninfectious
organisms. Other differences were noted between infectious and noninfectious isolates
by silver stain, and immunoprecipitation. P39 associated with three molecules
common to all isolates, and at least six additional molecules in noninfectious isolates
only. And finally, P39 surface expression was found to change in all uncloned isolates
during in vitro culture; uncloned isolates had a uniform decrease in surface expression
of P39 which corresponded with their loss of infectivity.
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ANIMAL STUDIES
Approximately 32 female, B6CBA strain, Mus musculus, ages six to 12 weeks,
were used in the following infectivity experiment. Mice were anesthetized with ether,
and blood samples were collected from each mouse using the retro-orbital technique.
Ether serves to minimize any pain the animals feel while blood is collected. Blood
samples were required to monitor any serological changes that occur during the
attempted infection process. Mice were inoculated with 0.1 ml of a Borrelia
burgdorferi suspension (100,000 organisms). Two to eight mice were used per isolate
(low or high passage). Fifteen days later mice received a 0.05 ml intraperitoneal
injection o f ketamine\xylazine solution. This causes the mice to sleep for
approximately twenty minutes. At this time 10-15 Ixodes scapularis nymphs were
allowed to feed on each mouse. Anesthetizing the mice allows the ticks a better
opportunity to attach and feed on the mice. Unanesthetized mice will readily eat the
ticks before they can attach. The ticks were used to determine if spirochetes can be
transmitted from infected mice to ticks as occurs in the wild. Four days after feeding
commences, the ticks were collected and held for processing. The mice were
anesthetized with ether and bled by the retro-orbital technique for reasons already
stated. The mice were euthanized by cervical dislocation (placing forceps at the base
of the mouse's skull and giving a quick and strong jerk on the tail). This method results
in complete ablation of central nervous system function and is approved by the Federal
Guide for the Care and Use of Laboratory Animals. The tissues were collected and
cultured in BSK-H media for detection o f B.burgdorferi.
Daily care for the animals was provided by the Animal Facility located in room
406, Mills Godwin building. The use and treatment o f the animals were approved by
the Animal Care and Use Committee of Old Dominion University. A mammalian host
was needed to determine the infectivity o f B.burgdorferi. Mice are reservoir hosts for
B.burgdorferi in the wild, and are commonly used in laboratory studies
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Appendix 1. Plasmid map of
pSPR33. P39 gene, bmpB gene,
ampicillin resistance gene, and
restriction sites are shown.
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Appendix 2. Plasmid map of
pCH110. LacZ gene, ampicillin
resistance gene, and restriction
sites are shown.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

94

3

_ 2
E
E

«

3

<

8c
(0

€o

ia i
£> «

<

0
5

10

15

20

25

30

35

Protein Concentration

Appendix 3. W estern blot densitom etry assessment. Densitometry absorbance
readings from a western blot o f serial dilutions of B. burgdorferi (protein concentration
given in pg) developed with monocionals specific for P39 ( • ) , Osp A (♦ ) and Osp B (■).
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